Official Protocol Title:
NCT number:
Document Date:
A Phase 2a, Multi-Center, Open-Label 
Study to Evaluate the Safety, Efficacy, and 
Pharmacokinetics of PRA023 in Subjects 
With Moderately to Severely Active Crohn's 
Disease 
[STUDY_ID_REMOVED]
28-June-2022
 
Clinical Protocol  PR200- 103 
A Phase 2a, Multi -Center, Open-Label Study to Evaluate  
the Safety,  Efficacy, and Pharmacokinetics of PRA023 
in Subjects  with Moderately to Severely Active Crohn’s Disease 
 
The APOLLO- CD Study 
 
EudraCT: 2021 -000092- 37 
 
Version 4.0 (28 June 2022) 
 
 
Study Sponsor: 
Prometheus Biosciences, Inc.  
[ADDRESS_1133767]  
San Diego, CA [ZIP_CODE] 
[LOCATION_003]  
 
Confidentiality Statement 
The information contained in this document is the property of Prometheus Biosciences, Inc. and 
is provided to you in confidence. The recipi[INVESTIGATOR_818583], Inc. This docume nt 
may be disclosed to applicable institutional review boards or other duly authorized regulatory agency 
representatives, as applicable, under the condition that confidentiality is maintained. 
 

PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 2 of 94 PROTOCOL APPROVAL PAGE 
Prometheus Biosciences , Inc. 
Protocol: PR200- 103 
A Phase 2a, Multi-Center, Open -Label Study to Evaluate 
the Safety,  Efficacy, and Pharmacokinetics of PRA023 
in Subjects  with Moderately to Severely Active Crohn’s Disease  
Version 4.0 (28 June 2022) 
Approved by:    
   
[CONTACT_813702], Inc.   Date  
  
  
30Jun2022
[COMPANY_003]
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 3 of 94 PROTOCOL SIGNATURE [CONTACT_818636] , Inc. 
Protocol: PR200-103  
Version 4.0 (28 June 202 2) 
By [CONTACT_27616] I confirm that I have read , and I understand this protocol “A Phase 2a, Multi-
Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects with Moderately to Severely Active Crohn’s Disease”, dated  [ADDRESS_1133768] this protocol as outlined herein in full accordance with the Principles of Good Clinical Practice and all applicable laws and regulations.  
 I will provide copi[INVESTIGATOR_443814] t o all information furnished by [CONTACT_818598], Inc. pertinent to the study to concerned personnel under my supervision. I will 
discuss the material with them to ensure that they are fully informed about the study.  I agree to implement the protocol procedures only after confirming that specimens were collected with informed consent/subject information approval from the Institutional Review Board/Independent Ethics Committee (IRB/IEC ) permitting such use. 
 I understand that all information supplied by [CONTACT_813702], Inc. is confidential, and I hereby [CONTACT_818599]/I EC, it will be 
submitted with a designation that the material is confidential.  
   
Investigator  Name    
[CONTACT_10670] ’s Signature   [CONTACT_818637]023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133769] OF STUDY PERSONN EL 
SPONSOR:  Prometheus Biosciences , Inc. 
[ADDRESS_1133770] : Prometheus Biosciences , Inc.  
PHARMACOVIGILANCE CONTACT:  . 
CLINICAL OPERATIONS CONTACT:  
   
[CONTACT_818600]023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 5 of 94 PROTOCOL VERSION AND  AMENDMENT TRACKING 
Version Number/Amendment  Date  
Version 1.1 30 April 2021 
Version 2.0 18 June 2021 
Version 2.1 for Belgium 28 June 2021 
Version 3.0 21 October 2021 
Version 3.1 for US A 19 January 2022 
Version 4.0 28 June 2022 
  
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133771] of Abbreviations .................................................................................................................... 11 Protocol Synopsis.......................................................................................................................... 14 1 Background and Rationale .................................................................................................... 25 1.1 Background ..................................................................................................................25 
1.2 Study Rati onale  ............................................................................................................26 
1.3 PRA023 Mechanism of Action and Nonclinical Data .................................................27 
1.3.1 Pharmacology .................................................................................................27 
1.3.2 Toxicology ......................................................................................................27 
1.4 Previous Human Experience ........................................................................................29 
1.4.1 Pharmacokinetic Results (PR200 -101 Healthy Volunteer Study) ..................29 
1.4.2 Safety Results  .................................................................................................30 
1.5 Dose Rationale  .............................................................................................................30 
1.6 Overall Benefit/Risk Assessment  .................................................................................[ADDRESS_1133772] Numbering and Randomization .........................................................38 
[IP_ADDRESS] Screening Numbers ....................................................................... 38 
[IP_ADDRESS] Randomization Numbers .............................................................. 39 
4.2 Study Subjects/Population ...........................................................................................39 
4.2.1 Inclusion/Exclusion Criteria  ...........................................................................39 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 7 of 94 [IP_ADDRESS] Inclusion Criteria  .......................................................................... 39 
[IP_ADDRESS] Exclusion Criteria  ......................................................................... [ADDRESS_1133773] X -Ray ....................................................................................................62 
6.3.4 Electrocardiogram (ECG) ...............................................................................62 
6.3.5 Clinical Laboratory Evaluations  .....................................................................62 
6.3.6 Stool Evaluation  ..............................................................................................64 
[IP_ADDRESS] Stool Culture  ................................................................................. 64 
[IP_ADDRESS] Screening for Clostridium  Difficile  .............................................. 64 
6.4 Effi 
cacy Assessment Description  .................................................................................64 
6.4.1 Ileocolonoscopy with Biopsy .........................................................................65 
[IP_ADDRESS] Ileocolonoscopy and SES- CD Score  ............................................ 65 
[IP_ADDRESS] Biopsy ........................................................................................... 66 
6.4.2 Crohn’s Disease Activity Index (CDAI) Score  ..............................................66 
6.4.3 Perianal Disease Activity Index (PDAI) .........................................................67 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 8 of 94 6.4.4 Fistula Drainage Assessment  ..........................................................................67 
6.4.5 Quality of Life (QoL) .....................................................................................67 
6.5 Pharmacodynamics ......................................................................................................67 
6.6 Pharmacokinetics .........................................................................................................68 
6.7 Immunogenicity (Anti -Drug Antibody) .......................................................................68 
6.8 Pharmacogenomics ......................................................................................................69 
6.9 Potential Future Research  ............................................................................................69 
7 Adverse Events and Serious Adverse Events ........................................................................ 70 
7.1 Pre-Treatment -Emergent Events ..................................................................................71 
7.2 Laboratory Abnormalities as Adverse Events ..............................................................72 
7.3 Grading/Severity of Adverse Events ............................................................................[ADDRESS_1133774] -Study Serious Adverse Events ....................................................75 
7.9 IRB/IEC Notification of Serious Adverse Events  ........................................................76 
7.10 Health Authority Safety Reports  ..................................................................................76 
7.11 Data Monitoring Committee (DMC) ...........................................................................76 
8 Assessment of Study Variables  ............................................................................................. 77 
8.1 Randomization .............................................................................................................77 
8.2 Justification of Sample Size  .........................................................................................77 
8.3 Evaluation of Safety Variables .....................................................................................77 
9 Statistical Methodology  ......................................................................................................... 79 
9.1 Analysis Populations ....................................................................................................79 
9.1.1 Safety Analysis Set (SAS) Population  ............................................................79 
9.1.2 F
ull Analysis Set (FAS) Population  ...............................................................79 
9.2 Statistical Analyses  ......................................................................................................79 
9.2.1 Demographics and Baseline Characteristics  ...................................................79 
9.2.2 Evaluation of Efficacy Parameters  .................................................................79 
9.2.3 Evaluation of Pharmacodynamic Parameters .................................................80 
9.2.4 Evaluation of Immunogenicity .......................................................................80 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 9 of 94 9.2.5 Evaluation of Exploratory Parameters ............................................................80 
9.2.6 Evaluation of Pharmacokinetic Parameters  ....................................................80 
9.2.7 Evaluation of Safety Parameters .....................................................................80 
[IP_ADDRESS] Adverse Events and Adverse Events of Special Interest  .............. 80 
[IP_ADDRESS] Medical History, Chest X -ray, ECGs and Physical 
Examination .................................................................................. 81 
[IP_ADDRESS] Clinical Laboratory and Vital Signs  ............................................. 81 
[IP_ADDRESS] Previous and Concomitant Medication  ......................................... [ADDRESS_1133775] Approval/ Independent Ethics 
Committee  ....................................................................................................................82 
10.3 Written Informed Consent ............................................................................................82 
10.4 Confidentiality  ..............................................................................................................82 
10.5 Protocol Modification/Amendments ............................................................................[ADDRESS_1133776] Access to Source Data/Documents  ...................................................................83 
11 Definition of End of Trial ...................................................................................................... 84 
11.1 End of Trial in a Member State  ....................................................................................84 
11.2 End of Trial in All Other Participating  Countries ........................................................84 
12 Data Management  .................................................................................................................. 85 
12.1 Coding of Adverse Events, Concomitant Medication, and Medical History ...............85 
13 Documentation and Administrative Considerations .............................................................. 86 13.1 Recordkeepi[INVESTIGATOR_007] ..............................................................................................................86 
13.2 Disclosure of Data ........................................................................................................86 
13.3 Publication Policy  ........................................................................................................86 
14 Quality Control and Quality Assurance ................................................................................ 88 
15 References  ............................................................................................................................. 89 
16 Appendix ............................................................................................................................... 92 16.1 Simple Endoscopic Score for Crohn’s Disease (SES -CD) ..........................................92 
16.2 Crohn’s Disease Activity Index (CDAI) ......................................................................93 
16.3 Perianal Disease Activity Index (PDAI) ......................................................................94 
  
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133777] OF TABLES  
 Schedule of Study Assessments – Screening Period  ...................................................52  
 Schedule of Study Assessments – Induction Period ....................................................54  
 Schedule of Study Assessments – Open -Label Extension Period ...............................56  
 Schedule of Study Asse ssments – Open -Label Extension Period (After Week 50) ....[ADDRESS_1133778] OF FIGURES  
Figure 1  Study Schema...............................................................................................................38  
 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133779] 
measurable concentration, estimated by [CONTACT_818601]’s disease  
CDAI  Crohn’s disease activity index  
CDC  Complement -dependent cytotoxicity  
CDx  Companion diagnostic  
CFR  Code of Federal Regulations  
CK Creatine kinase  
Cmax Maxim um concentration  
CMV  Cytomegalovirus  
CNS  Central nervous system  
COVID -[ADDRESS_1133780] Research Organization  
CS Clinically significant  
CTA  Clinical trial application  
CTCAE  Common Toxicity Criteria for Adverse Events  
CV Coefficient of variation  
DILI  Drug induced liver injury  
DMC  Data Monitoring Committee  
DMP  Data management plan  
DNA  Deoxyribonucleic acid  
DR3  Death receptor 3  
DSS Dextran sodium sulfate  
EC Ethics Committee  
eCRF  Electronic c ase report form  
ECG  Electrocardiogram  
EDC  Electronic data capture  
eDiary  Electronic diary  
EFD  
EHI Embryo -fetal development  
Endoscopic healing index  
ET Early termination  
FAS Full Analysis Set 
FcR Fc receptor  
FDA  Food and Drug Administration  
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133781] term  Explanation  
FSH Follicle stimulating hormone  
FU Follow -Up 
GCP  Good Clinical Practice  
GD Gestational day  
GDH  Glutamate dehydrogenase  
GGT  Gamma -glutamyl transferase  
GHAS  Global histological activity score  
GI Gastrointestinal  
GLP  Good Laboratory Practice  
GM Geometric mean  
HBsAg  Hepatitis B surface antigen  
HBcAb  Hepatitis B core antibody  
HCV  Hepatitis C virus  
HDL  High density lipoprotein  
Hgb Hemoglobin  
HIV Human immunodeficiency virus  
hsCRP  High sensitivity C -reactive protein  
IBD Inflammatory bowel disease  
IBDQ  Inflammatory Bowel Disease  Questionnaire  
ICF Informed consent form  
ICH International Conference on Harmonisation  
IEC Independent Ethics Committee  
IFN-γ Interferon gamma  
IgG Immunoglobulin G  
IgG 1κ Immunoglobulin G subtype G 1 kappa  
IgM Immunoglobulin M 
IL-12/23  Interleukin -12/[ADDRESS_1133782] level  
NS Normal saline  
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133783] deviation  
SES-CD Simple endoscopy score for Crohn’s disease  
SOC  System organ class  
sTL1A  Soluble tumor necrosis factor -like cytokine 1A  
SOP Standard operating procedure  
S[LOCATION_003]R  Suspected, unexpected serious adverse  reaction  
t1/[ADDRESS_1133784]  Upper limit of normal  
VLDL  Very low density lipoprotein  
WBC  White blood cell  
WHO -DD World Health Organization – Drug Dictionary  
WK Week  
WOCBP  Women of childbearing potential  
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 14 of 94 PROTOCOL SYNOPSIS  
TITLE:  A Phase 2a, Multi -Center , Open -Label  Study to Evaluate the Safety, 
Efficacy, and Pharmacokinetics of PRA023 in Subjects with Moderately to 
Severely Active Crohn’s Disease  
PROTOCOL NUMBER:  PR200 -[ADDRESS_1133785] PHASE:  Phase 2a 
OBJECTIVE:  Primary:  
• To evaluate the safety and tolerability of PRA023 following 12-weeks 
of induction therapy  
• To assess the proportion of subjects with endoscopic improvement 
(decrease in simple endoscopy score for Crohn’s disease [ SES-CD] 
≥ 50% from Baseline) at Week 12   
Secondary:  
• To assess the proportion of subjects with clinical remission ( Crohn’s 
disease activity index [ CDAI ] < 150) at Week 12 
• To assess the proportion of subjects with endoscopy and clinical 
improvement (decrease in SES -CD ≥ 50% AND reduction in CDAI 
≥ 100 points  from Baseline) at Week 12  
• To assess the proportion of subjects with biomarker and clinical 
improvement (decrease in high sensitivity C -reactive protei n [hsCRP] 
or fecal calprotectin ≥ 50%  from Baseline , among subjects with at least 
one elevated biomarker at Baseline, AND reduction in CDAI ≥ 100 
points  from Baseline) at Week 12   
• To assess the proportion of subjects with normalization of C-reactive 
protein (hsCRP < upper limit of normal  [ULN]), among subjects with 
elevated concentrations at Baseline, at Week 12  
• To assess the proportion of subjects with normalization of fecal 
calprotectin (fecal calprotectin < ULN), among subjects with elevated concentrations at Baseline,  at Week 12  
• To assess the proportion of subjects with clinical improvement 
(reduction in CDAI ≥ 100 points  from Baseline) at Week 12  
• To assess the proportion of subjects with two component patient -
reported outcome  (PRO-2) remission (average daily abdominal pain 
score ≤ 1 point and average daily stool frequency ≤ 3 points with 
abdominal pain and stool frequency no worse than Baseline  at Week 12 ) 
• To assess the change in SES -CD score from Baseline to Week 12  
• To assess the pharmacokinetics (PK) of PRA023  
• To assess the immunogenicity of PRA023 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 15 of 94 Exploratory:  
• To assess the change in CDAI and component scores over time  
• To assess the effects of PRA023 on tissue and serum pharmacodynamic 
(PD) markers, including tumor necrosis factor -like cytokine 1A 
(TL1A ) concentrations , endoscopic healing index (EHI), fecal 
calprotectin, and hs CRP in all subjects over time  
• To assess the change in SES -CD at Week 5 0 from Baseline  
• To characterize the change in P erianal Disease A ctivity Index (PDAI) 
score from Baseline to Week 12, Week 28, and Week 5 0 
• To characterize the effect of PRA023 for improvement and remission 
of enterocutaneous and/or perianal fistula during the Induction Period 
(IP) and Open -Label Extension ( OLE ) 
• To assess all secondary endpoints at Week 5 0 
• To assess the change in g lobal h istological a ctivity s core (GHAS) and 
Robarts histopathology index (RHI) from Baseline to Week 12 and 
Week 5 0 
• To assess the proportion of subjects with histologic response  and 
histologic remission at Week 12 and Week  50 
• To assess change in PRO-2 over time  
• To assess change in extraintestinal manifestations over time  
• To assess long -term safety, tolerability, and efficacy of PRA023  
STUDY DESIGN:  This is a multi -center, open -label, proof of concept study designed to assess 
the safety, tolerability, and preliminary efficacy of PRA023 following 12 weeks of induction therapy in subjects with Crohn’s disease ( CD). This 
study will be conducted under the aegis of a D ata M onitoring Committee  
(DMC ) and will commence following the demonstration of an acceptable 
safety profile of PRA023 at a dose of ≥ 500 mg in the multiple  ascending 
dose study in normal healthy volunteers (Study PR200 -101) . 
 The study has 4 periods (Screening, IP, OLE  and Follow -Up [F U] Period). 
Following the Screening Period, approximately 50 eligible subjects with moderately to severely active CD will enter the IP to receive PRA023 1000 
mg on Week 0/Day 1, followed by 500 mg on Weeks 2, 6, and 10 via 
intravenous (IV) administration. Subjects who discontinue from the study drug will have a follow -up period of [ADDRESS_1133786] dose.  
 Response at Week 12 will be defined as reduction from Baseline in CDAI 
of ≥ [ADDRESS_1133787] the 
option to enter OLE , where they will be randomized to either 250 mg IV 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 16 of 94 Q4W or 100 mg IV Q4W until Week 134 Subjects will continue in OLE 
until they progress, withdraw from the study, study termination , or Week 
134.  
The study is being amended by [CONTACT_813670] 50 weeks to Week 134 based on emerging safety data in both this 
study as well as a concurrent double -blind Phase 2 study in ulcerative 
colitis . The OLE period may be further extended beyond 134 weeks based 
on emerging safety data in a future amendment . 
SAMPLE SIZE:  The study is planned to enroll approxim ately 50 subjects. The sample size 
will enable a statistical power of 80% , at 1-sided significance level of 
0.025, to test against the null hypothesis of endoscopic improvement rate of 
12%, assuming the endoscopic improvement rate for PRA023 is 27%.  
SUBJECT TYPE:  Male or female subjects ≥ 18 years of age  with moderately to severely 
active CD. 
FORMULATIONS:  PRA023 will be supplied in 10 mL vials each containing 500 mg PRA023  
(60 mg/mL concentrate for solution  for infusion) for IV administration after 
reconstitution . 
DOSAGE:  Induction Period: all subjects will receive PRA023 1000 mg on Week 
0/Day [ADDRESS_1133788] the option to enter the OLE , where 
all subjects will be randomized to receive one of the following regimens  
until disease progress ion, withdraw from the study, study termination , or 
Week 134. 
• PRA023 250 mg IV on Week 1 4 then Q4W 
• PRA023 100 mg IV on Week 1 4 then Q4W 
ROUTE OF 
ADMINISTRATION:  The study drug  will be reconstituted in 250 mL of 0.9% normal saline ( NS) 
and will  be administered IV over 30 minutes . 
STUDY ENDPOINT S: Primary endpoints:  
• Safety and tolerability: the proportion of subjects reporting adverse 
events (AEs), serious adverse events (SAEs), AEs leading to 
discontinuation, and markedly abnormal laboratory values  
• The proportion of subjects with endoscopic improvement, as defined by [CONTACT_818602] -CD ≥ 50% from Baseline at Week 12  
Secondary endpoints:  
• The proportion of subjects in clinical remission (CDAI <  150) at 
Week  12 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 17 of 94 • The proportion of subjects with endoscopic and clinical improvement , 
as defined by [CONTACT_818602] -CD ≥ 50% AND reduction in CDAI 
≥ 100 points from Baseline at Week 12 
• The proportion of subjects with both biomarker and clinical 
improvement (decrease in hsCRP OR fecal calprotectin ≥ 50%  from 
Baseline, among subjects with at least one elevated biomarker at 
Baseline, AND reduction in CDAI ≥ 100 points  from Baseline) at  
Week 12  
• The proportion of subjects with normalization of hsCRP (as defined by 
[CONTACT_53832] < ULN), among subjects with elevated concentrations at Baseline,  at Week 12  
• The proportion of subjects with normalization of fecal calprotectin (as defined by [CONTACT_818603] < ULN ), among subjects with elevated 
concentrations at Baseline, at Week 12  
• The proportion of subjects in clinical response, as defined by [CONTACT_818604] ≥ 100  points from Baseline at Week 12  
• The proportion of subjects with  PRO- 2 remission ( defined as average 
daily abdominal pain score ≤ 1 point and average daily stool frequency 
≤ 3 points with abdominal pain and stool frequency no worse than 
Baseline)  at Week 12  
• Change in SES -CD score at Week 12 from Baseline  
• Descriptive summaries of PK and immunogenicity of PRA023 
• Proportion of subjects developi[INVESTIGATOR_84065] -drug antibody ( ADA) and 
neutralizing antibody (Nab)  
Exploratory endpoints: 
• Change in CDAI and components from Baseline over time 
• Change in PD markers including TL1A concentrations , EHI, fecal 
calprotectin, and hs CRP over time  
• Change in SES -CD from Baseline at Week 5 0 
• Change in PDAI from Baseline over time  
• Proportion of subjects with improvement or remission of 
enterocutaneous and/or perianal fistula at Week 12 and Week 50 
• Change in GHAS and RHI from Baseline to Week 12 and Week 50 
• The proportion of subjects with GHAS histologic score ≤ 4 at Week 12 
and Week 5 0 
• The proportion of subjects with Robarts histologic score <  5 at Week 
12 and Week 5 0 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 18 of 94 • The proportion of subjects with GHAS histologic remission, defined as 
no neutrophils in the epi[INVESTIGATOR_818584] 0, at Week 12 and Week  50 
• The proportion of subjects with Robarts histologic remission (<  3) at 
Week 12 and Week 5 0 
• Change in PRO -2 over t ime 
• The proportion  of subjects with extraintestinal manifestation through 
Week 50 
• The long-term safety, tolerability, and efficacy of PRA023 through 
Week 13 4 
INCLUSION 
CRITERIA:  Subjects are required to meet the following criteria in order to  be included in 
the study:  
1. Male or female ≥ [ADDRESS_1133789] had a diagnosis of CD ( confirmed  by [CONTACT_235127] + 
histology) at least [ADDRESS_1133790] be confirmed at time of screening colonoscopy . Note 
that mention of “chronic inflammation” or “Crohn’s disease” or equivalent on histology report is acceptable.  
3. Moder ately to severely active CD as defined by [CONTACT_818605] ≥ 220 and 
≤ 450. 
4. SES-CD score (per central reading) ≥ 6 if ileocolonic or colonic disease; or ≥ [ADDRESS_1133791] one  of the following criteria:  
a) In the past,  had an inadequate response to one or more of the 
following treatments:  
• Oral prednisone ≥ 40 mg/day (or equivalent) or budesonide ≥ 9 mg/day or equivalent or beclomethasone ≥  5 mg/day for at 
least 2 weeks  
• Corticosteroid dependence as defined by [CONTACT_813676] < 10 mg/day of prednisone or equivalent (i.e., had a flare of disease) within 3 months of starting therapy, or if relapse occurs within 3 months of stoppi[INVESTIGATOR_657109]  
• Immunosuppressants (azathioprine ≥ 2 mg/kg/day or 6-mercaptop urine ≥ 1.0 mg/kg/day, [or documentation of a 
therapeutic concentration of 6-thioguanine nucleotide] or methotrexate ≥ 15 mg/week) for at least 8 weeks. Note: a lower 
dosage of 6- MP or AZA is acceptable if local guidelines specify 
a different treatment regimen  (which would need be 
documented in the source  document)  
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 19 of 94 • An approved anti -TNF agent at an approved labeled dose for at 
least 8 weeks  
• An approved anti -integrin (e.g., v edolizumab ) at an approved 
labeled dose for at least 8 weeks  
• An approved anti -IL-12/23 (e.g. , ustekinumab) at an approved 
labeled dose for at least 8 weeks  
OR 
b) Had been intolerant to one or more of the above mentioned 
treatments (e.g ., unable to achieve doses or treatment durations 
because of dose-limiting side effects [e.g., leukopenia, psychosis, 
uncontrolled diabetes, elevated liver enzymes])  
OR 
c) Currently  receiving one or more of the following treatments:  
• Oral Prednisone ≥  10 mg/day (or equivalent) or budesonide 
≥ 3 mg/day or beclomethasone ≥  5 mg/day for at least 3 months  
• Immunosuppressants [azathioprine ≥ 2 mg/kg/day or 
6-mercaptopurine ≥  1.0 mg/kg/day, (or documentation of a 
therapeutic concentration of 6-thioguanine nucleotide)] for at 
least 8 weeks. Note: a lower dosage of 6- MP or AZA is 
acceptable if local guidelines specify a different treatment  
regimen  (which would need be documented in the source  
document)  
Notes on subjects who have had prior approved biologic therapy(ies) 
(e.g., anti-TNF , anti-integrin , and/or anti-IL-12/23):  
• The study will include a maximum of 70 % and a minimum of 
approximately 5 0% subjects who have had prior  approved biologic 
therapy(ies) experience. Upon reaching the maximum number of 
allowed biologic experienced subjects (70%), subjects who have 
had prior biologic experience will no longer be a llowed to enter the 
study.  Upon reaching the maximum number of allowed biologic -
naïve subjects ( approximately  50%), subjects who have never been 
exposed to a  prior biologic will no longer be allowed to enter the 
study.    
• Subjects cannot have had failed (no response, insufficient response, 
loss of response,  and/or intolerance) > 4 approved biologic 
therapi[INVESTIGATOR_014], whether of same or different mechanism of action  
• Subjects previously on clinical trials only ( i.e., did not receive 
commercial available therapy post -approval) are not considered to 
have received the approved therapy for purpose of this inclusion 
criteria  
6. For subjects who are women of childbearing potential (WOCBP) involved in any sexual intercourse that could lead to pregnancy, the subject has used two highly effective methods of contraception for at 
least 4 weeks prior to Day 1 and agrees to continue to use two highly 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133792] meet drug stabilization requirements, as applicable:  
a) Oral corticosteroid treatment must be  equivalent of ≤ 20 mg 
prednisone or ≤ 9 mg budesonide or beclomethasone ≤  [ADDRESS_1133793] 2 weeks prior to Day 1  
b) Oral aminosalicylates should be at a stable dose for at least 2 
weeks prior to Day 1  
c) Azathi oprine, 6-mercaptopurine, and methotrexate should be at a 
stable dose for at least 4 weeks prior to Day 1  
9. Able to provide written informed consent and understand and comply 
with the requirements of the study . 
EXCLUSION 
CRITERIA:  Subjects with the following characteristics will be excluded from the study:  
Sex and Reproductive Status  
1. WOCBP and men with female partners of childbearing potential who 
are unwilling or unable to use two highly effective  methods of 
contraception  to avoid  pregnancy for the entire study period and for up 
to [ADDRESS_1133794] on enrollment or prior to Day 1 . 
Target Disease Exceptions 
4. Diagnosis of ulcerative colitis  or indete rminate colitis . 
5. CD isolated to the stomach, duodenum, jejunum, or perianal region, without colonic and/ or ileal involvement . 
6. Suspected or diagnosed intra -abdominal or perianal abscess at 
Screening . 
7. Known symptomatic stricture or stenosis not passable in endoscopy (including pediatric colonoscope) . 
8. Current stoma or need for colostomy or ileostomy . 
9. Previous small bowel resection with combined resected length of 
> 100 cm or previous colonic resection of >  2 segments . 
10. Currently receiving total parenteral nutr ition. 
11. Surgical bowel resection within 3 months before screening. 
12. Concomitant primary sclerosing cholangitis (PSC) . 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133795] a history of clinically significant drug or alcohol abuse. 
16. Concomitant illness that in the opi[INVESTIGATOR_689], is likely to require systemic glucocorticosteroid therapy during the study 
(e.g., moderate to severe asthma) . 
17. Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, pulmonary, cardiac, neurological, ophthalmologic , or cerebral disease. Concomitant medical conditions 
that in the opi[INVESTIGATOR_818585] . 
18. Subjects with a history of cancer within the last 5 years (other than non-melanoma skin cell cancers cured by [CONTACT_109413]). Existing non-melanoma skin cell cancers must be removed prior to enrollment. 
Subjects with carcinoma in situ  or localized cervical cancer, treated 
with definitive surgical intervention, are allowed . 
19. Subjects at risk for tuberculosis (TB). Specifically, subjects with: 
a) A history of active TB  
b) Current clinical, radiographic , or laboratory evidence of active TB  
c) Latent TB which was not successfully treated. Subjects with a positive TB screening test indicative of latent TB will not be eligible for the study unless active TB infection has been ruled out, 
and an appropriate course of intervention for latent TB has been 
initiated at least [ADDRESS_1133796] 3 months, 
unless treated and resolved with antibiotics, or any chronic bacterial 
infection (such as chronic pyelonephritis, osteomyelitis, and 
bronchiectasis). 
21. Female subjects who have had a breast cancer screening that is 
suspi[INVESTIGATOR_109373], and in whom the possibility of malignancy cannot be reasonably excluded following additional clinical , laboratory , 
or other diagnostic evaluations . 
22. Subjects with any active infections (excluding fungal infections of nail 
beds) including, but not limited to, those that require IV antimicrobial 
treatment 4 weeks or oral antimicrobial treatment 2 weeks prior to randomization. S ubjects with evidence of Human Immunodeficiency 
Virus (HIV), Hepa titis B , or Hepatitis C  infection  detected during 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 22 of 94 screening  are also excluded, but s ubjects with successfully treated 
Hepatitis C with no recurrence for ≥ [ADDRESS_1133797] positivity within 2 
weeks of randomization are excluded.  
23. Subjects with herpes zoster reactivation or cytomegalovirus (CMV) 
that resolved less than [ADDRESS_1133798] Findings 
25. Positive stool Polymerase Chain Reaction ( PCR) if I nvestigator deems 
this positivity reflects infection rather than colonization or  positive 
culture for enteric pathogens .  Subjects who have an infection can be 
retested after the completion of a full course of treatment. 
26. Stool positive for Clostridium  difficile  (C. difficile ) toxin . Subjects who 
are positive can be retested after the completion of a full course of treatment for C.  difficile  infection. 
27. Any of the following lab values:  
a) Hemoglobin ( Hgb) < 8.0 g/dL  (80 g/L)  
b) White blood cell ( WBC) < 2,500/mm
3 (2.5 x 109/L) 
c) Neutrophils < 1,000/mm3 (1 x 109/L) 
d) Platelets < 100,000/mm3 (100 x 109/L) 
d) Serum creatinine > [ADDRESS_1133799]  
e) Serum alanine aminotransferase ( ALT ) or aspartate 
aminotransferase (AST ) > [ADDRESS_1133800]  
f) Any other laboratory test results that, in the opi[INVESTIGATOR_689],  might place the subject at unacceptable risk for 
participation in this study. 
Prohibited Therapi[INVESTIGATOR_13265]/or Medications  
28. Failed (no response, insufficient response, loss of response, and/or 
intolerance) > 4 approved biologic thera pi[INVESTIGATOR_014] (anti-TNF, anti-integrin, 
anti-IL12/23) , whether of same or different mechanism of action . 
29. Any marketed biologic within 8 weeks  for anti -TNF agents and 12 
weeks for anti -integrin agents (e.g. , vedolizumab ) and ustekinumab 
prior to  Day 1  or if drug level per therapeutic dose monitoring is 
greater than lower limit of detection . 
30. Any biologic immunomodulators used for CD or other conditions 
within 8 weeks or 5 half -lives , whichever is longer, prior to Day 1 or if 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 23 of 94 drug level per therapeutic dose  monitoring is greater than lower limit of 
detection . 
31. Rituximab within 1 year prior to Day 1 . 
32. Parenteral corticosteroids within 4 weeks or rectal administration of 
corticosteroids within 2 weeks prior to Day 1 . 
33. Rectal administration of 5- ASA within 2 weeks prior to Day 1 . 
34. Tacrolimus, cyclosporine, mycophenolate mofetil (CellCept®), 
immunoadsorption columns (such as Prosorba columns), D Penicillamine, Leflunomide, Thalidomide, chronic use of non-steroidal 
anti-inflammatory agents (NSAIDs), and aspi[INVESTIGATOR_248] > 81 m g/day within  2 
weeks prior to Day 1 . 
35. Other investigational chemical agent within 30 days or other investigational biologic agent within 8 weeks or 5 half -lives (whichever 
is longer) of entry into the IP . 
36. Prior exposure to PRA023. 
Other Exclusion Criteria  
37. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness. 
38. Legal or mental incapacitation, or inability to understand and comply with the requirements of the study . 
39. Known allergies, hypersensitivity, or intolerance to PRA023 or its excipi[INVESTIGATOR_840].  
Statistical Methods:  Statistical methods will be detailed in the Statistical Analysis Plan  (SAP) . 
The SAP will provide details about methods of analysis and the specific planned analyses, and will be p repared and approved by [CONTACT_818606].  
The analysis populations are defined as follows: 
• Full analysis set (FAS): all subjects treated with Baseline SES- CD sco re 
• Safety analysis set: all subjects treated  
The following analyses will be performed : 
Efficacy: 
The primary efficacy endpoint, endoscopic improvement at Week 12, will 
be used to assess the efficacy of PRA023. The proportion of subjects in the per-protocol  population with endoscopic improvement will be tested 
against the null hypothesis of endoscopic improvement rate of 12% , at a [ADDRESS_1133801] the null hypothesis of clinical remission rate of 16%, at a 1 -sided 
significance level of 0. 025.  
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 24 of 94 The point estimates for the primary and secondary endpoints will be 
calculated along with 95 % confidence interval an d by [CONTACT_818607] ( CDx ) status (CDx+ or CDx -).  
Adverse Events:  
AEs will be coded using the most current version of Medical Dictionary for 
Regulatory Activities (MedDRA®). 
A by -subject AE data listing, including verbatim term, preferred term  (PT), 
system organ class (SOC), treatment, severity, seriousness criteria, 
relationship to drug, and action taken, will be provided.  
The number of subjects experiencing treatment -emergent adverse events 
(TEAEs) and number of TEAEs will be summarized by [CONTACT_818608] . 
Medical History, c hest x -ray, electrocardiogram ( ECG ), and p hysical 
examination will be listed by [CONTACT_1130].  
Changes in ECGs and physical examinations will be described in the text of the final report. 
Concomitant Medications: 
Concomitant medications will be coded using the most current World 
Health Organization ( WHO) drug dictionary and listed by [CONTACT_3148].  
Pharmacokinetics:  
Summary statistics of PRA023 concentrations and ADA by [CONTACT_765].  
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 25 of 94 1 BACKGROUND AND RATIONALE  
1.1 Background 
PRA023 is a humanized monoclonal antibody that binds human tumor necrosis factor- like 
cytokine 1A (TL1A) with high affinity and specificity. TL1A is a cytokine which is part of the 
tumor necrosis factor (TNF) superfamily protein and is  secreted by [CONTACT_818609].  
TL1A binds to death receptor 3 (DR3) that is found primarily on T cells, natural killer (NK) and 
NK-T cells, innate lymphoid cells (ILC), and epi[INVESTIGATOR_1663] ( Valatas 201 9) and potently drives 
Th1, Th2, Th9, and Th17 responses. In addition, TL1A is induced in antigen -presenting cells by 
[CONTACT_818610] (TLR) ligands and FcR  (Fc receptor)  cross- linking and in T cells by T -cell 
receptor (TCR) stimulation (Prehn 2007). TL1A occurs as both membrane -bound and soluble 
forms ( Ferdinand 2018).  
TL1A has been shown to be upregulated in mucosa and serum of patients with inflammatory 
bowel disease (IBD) ( Bamias 2003, Bamias 2010). TL1A and DR3 are abundantly localized at 
inflamed intestinal areas of patients with IBD and mice with experimental ileitis or colitis and 
actively participate in the immunological pathways that underlie mucosal homeostasis and 
intestinal inflammation ( Valatas 2019 ). Furthermore, TL1A polymorphisms have been shown to 
be associated with susceptibility to IBD ( Yamazaki 2005, Yang 2008) and with disease severity 
(Cleynen 2013, Richard 2015).  
In dextran sodium sulfate (DSS) and adoptive transfer mouse models, antibodies against TL1A led 
to reduced inflammation and reversal of fibrosis, even when treatment was administered late in the 
course of disease, after inflammation and fibrosis has been established ( Shih 2014).  
Prometheus Biosciences has developed PRA023, a humanized IgG1 kappa (IgG1κ ) monoclonal 
antibody that binds to both membrane-bound and soluble forms of TL1A with high affinity and 
specificity and blocks the binding of TL1A to its functional receptor DR3. Prometheus 
Biosciences is also developi[INVESTIGATOR_007] a genetic-based companion diagnostic ( CDx ) to identify patients 
who are predisposed for increased expression of TL1A and therefore potentially more likely to 
respond to PRA023. By [CONTACT_813682], PRA023 has the 
potential to substantially improve outcomes for  moderate to severe IBD patients with increased 
TL1A expression. 
PF-06480605 is an anti -TL1A monoclonal antibody developed by [CONTACT_813683] ( UC) ( Banfield 2020, Danese 2020). T arget 
engagement was demonstrated in healthy volunteers as confirmed by [CONTACT_2715]- dependent increases 
in mean total soluble tumor necrosis factor -like cytokine 1A ( sTL1A ). In a Phase 2a open- label 
study with centrally read endoscopy in subjects with moderately to severely active UC, treatment 
with the anti -TL1A antibody led to significant endoscopic improvement (38%), clinical 
remission (24%), histologic improvement, and decrease in biomarkers (fecal calprotectin and 
high sensitivity c- reactive protein [ hsCRP ]) at Week 14. PF-[ADDRESS_1133802] an 
acceptable safety and tolerability profile.  
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 26 of 94 Prometheus Biosciences is undertaking a Precision Medicine approach to the development of an 
anti-TL1A therapeutic for treatment of moderate to severe Crohn’s Disease (CD) and UC, using a 
CDx to identify patients most likely to respond to study drug. The advantage of this unique, 
precision -based approach in IBD is the ability to identify patients more likely to respond to our 
therapeutics in targeted clinical trials, with the ultimate goal of bringing therapeutic drugs to 
patients with significantly better clinical efficacy.  
This study is a P hase 2a , open- label  study designed to evaluate the safety, efficacy , and 
pharmacokinetics ( PK) of PRA023 in subjects with moderately to severely active CD.  
1.[ADDRESS_1133803] common forms of IBD. Both UC and CD are chronic, relapsing, remitting, inflammatory conditions of the gastrointestinal (GI) tract that begin most commonly during adolescence and young adulthood. UC involves the mucosal  
layer of the large intestine, and symptoms include abdominal pain and diarrhea, frequently with blood and mucus. CD can affect the entire thickness of the bowel wall and all parts of the GI tract from mouth to anus. CD symptoms include abdominal pain, diarrhea, and other more insidious  
symptoms such as weight loss, nutritional deficiencies, and fever. The prevalence of IBD  globally 
is approximately 5 million and affects over 2 million people in the US ( Ananthakrishnan 2020).  
A hallmark of IBD is the cytokine respo nses that govern the initiation, evolution, and ultimately, 
the resolution of these forms of inflammation. Many immune cells, cytokines, and chemokines of the adaptive and innate immune systems play a role in IBD, including but not limited to IL -12, 
IL-23, IFNγ, IL-17, IL-22, and TL1A ( Roberts ‑Thomson 2011, Strober 2011). 
The curre nt standard of care for the treatment of patients with moderate to severe IBD are 
generally immunomodulatory agents that are anti-inflammatory. None of the therapi[INVESTIGATOR_818586]. Since the approval of the first anti- TNF agent for the treatment of CD in 1998, 
the availability of newer biological agents, including anti -integrin  (vedolizumab  and natalizumab ) 
and anti- IL-12/23 (ustekinumab) has improved the care of moderate to severe CD. However, 
none of these subsequently approved therapi[INVESTIGATOR_818587] -TNF . Moreover, among those patients who do respond, up to 45% will 
lose response over time ( Roda 2016).  Current therapi[INVESTIGATOR_818588] a 
one-size-fits-all approach without regard to genetic or biologic variations in the patient. Existing 
approaches continue to le ave unmet patient need.  
Given established clinical validation of the target with PF-06480605, the current open- label 
Phase 2a study is designed to demonstrate the efficacy of PRA023 in subjects with moderately to severely active CD. In addition, this study is designed to assess the effectiveness of the genetic CDx  for the purpose of selection of subjects whose disease is driven by [CONTACT_818611]1A pathway and 
therefore, have a higher response rate to treatment with an anti -TL1A antibody. The study is also 
designed with an open-label extension study to ensure that subjects who benefit from the therapy have the option to continue therapy.  
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 27 of 94 In parallel, a randomized, placebo- controlled study (PR200 -102) w ill be conducted to demonstrate  
the proof of concept of PRA023 for induction therapy in subjects with moderately to severely active UC.  
1.3 PRA023 Mechanism of Action and Non clinical Data  
The Investigator’s Brochure should be referenced for a complete summary of data and information 
collected about PRA023  (including the principal data and findings from the nonclinical 
pharmacology, pharmacokinetic, and toxicology studies conducted to date). 
1.3.1 Pharmacology  
PRA023 is a humanized IgG1κ  antibody that binds human TL1A  with high affinity and specificity  
and neutralizes TL1A functional activity in vitro and ex vivo cell-based assays. PRA023 binds to 
both human and cynomolgus TL1A with a similar sub-nanomolar EC 50 (half maximal effective 
concentration) and with similarly high affinity (K D [dissociation constant] values of  and 
 res
pectively). In addition, PRA023 is specific for TL1A and does not bind to other 
TNF super family members. Together, these data show that PRA023 is a high affinity humanized monoclonal antibody with selectivity for human and cynomolgus TL1A. 
PRA023 has the capacity to block human TL1A-induced caspase activation and apoptosis in the 
TF-1 functional assay with an IC
50 (half maximal inhibitory concentration) of  Similarly, 
PRA023 bl
ocked monkey TL1A -induced caspase activation with an IC 50of  In a monkey 
whole blood assay, PRA023 inhibited the immune complex/TL1A enhancement of interferon gamma ( IFN-γ) release with an IC
50 of  and IC 90 (90% maximal inhibitory c oncentration)  
of . 
A single dose PK/PD study in cynomolgus monkeys demonstrated a dose-dependent pharmacologic effect of PRA023 on the inhibition of TL1A- mediated IFN -γ release from 
peripheral blood mononuclear cells ( PBMCs ) in whole blood at doses of . The 
observat 
ion that greater concentrations  of serum PRA023 were required 
to elicit this effect in animals treated with PRA023 versus when PRA023 was added in vitro to monkey whole blood indicates that a higher concentration of drug is required for biologic effect in vivo. In addition, a dose -dependent increase in circulating sTL1A concentrations was observed  
at all dose levels. This suggests that systemic sTL1A concentrations may be a useful PD marker for target eng agement by [CONTACT_29663]023. 
1.3.2 Toxicology  
Six-week and 6- month Good Laboratory Practice ( GLP) repeat -dose toxicity stud ies were  conducted 
in cynomolgus  monkeys with a 6- week recovery period  and a definitive GLP embryo- fetal 
development (EFD) study was conducted in New Zealand White rabbits. The intravenous (IV) 
route of administration was selected  for these studies since it is the route of clinical 
administration. In addition, a series of in vitro studies were conducted with PRA023 including Fc effector function (i .e., antibody- dependent cellular cytotoxicity [ ADCC ], complement -dependent 
cytotoxicity [ CDC], and antibody-dependent phagocytosis cytotoxicity [ADCP] ) assays, human 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 28 of 94 cytokine release assays, and a GLP tissue cross-reactivity study using human and monkey 
tissues.  
Stand -alone safety pharmacology studies were not conducted with PRA023. Cardiovascular, 
central nervous system (CNS), and respi[INVESTIGATOR_818589] -dose IV toxicity studies  in monkeys. There were no func tional cardiovascular,  CNS , 
or respi[INVESTIGATOR_818590]023 at ≤  300 mg/kg/week for up to [ADDRESS_1133804] level (NOAEL) in  the 6-month study was considered to be 300 
mg/kg/week (the highest dose tested). No PRA023 -related mortality; adverse clinical 
observations; body weight or body weight alterations; hematology, coagulation, or urinalysis effects; organ weight effects; macroscopic observations; microscopic findings; ECG findings; 
ophthalmic or neurobehavioral observations or findings in  body temperature or respi[INVESTIGATOR_818591] 6 months of repeat dosing in monkeys. No 
PRA023 -related effects were noted in mean absolute counts or  relative proportions of 
lymphocyte subse ts (total T cells, helper and cytotoxic T cells, B cells, NK cells, monocytes, and 
regulatory helper and cytotoxic T cells) at ≤ 300 mg/kg/week as measured by 
[CONTACT_137766][INVESTIGATOR_007], compared with the  controls . All a nimals mounted a robust anti- KLH IgG 
and IgM response, suggesting an intact humoral immunity. There  were no organ weight changes, 
or macroscopic or microscopic observations in male or female reproductive organs after 6  
months repeat dosing of PRA023 administration in sexually mature monkeys. A normal progression of the spermatogenic cycle and the expected cell associations and proportions in the 
various stages of spermatogenesis were noted in the testes.  
After  IV administration of PRA023 to monkeys in the 6- week repeat -dose toxicity study, 
findings that  were secondary  to generation of ADA and immune complex deposition in response 
to administration of a foreign protein (humanized monoclonal antibody) to immunocompetent 
animals (including the death of one low dose animal) were observed. Similar findings were not observed in the 6-month monkey toxicity study using the same dosing regimen and dose levels confirming that the findings in the 6- week repeat -dose toxicity study were secondary to ADA 
formation and not directly related to the mechanism of action of PRA023.  
Based on the NOAEL of 300 mg/kg/week, t he exposur
 e margin (based on area under the curve from 
0 to 168 hr [ AUC 0-168hr] after repeat dosing;  at the NOAEL is , r elative 
to the projected AUC 0-672hr (  after the last 500 mg induction dose (i.e., highest 
predicted  exposure due to accumulation of repeat dosing) in the dosing regimen. Similarly, for 
maximum concentration ( Cmax), the exposure margin (based on C max after repeat dosing ;  
 at the NOAEL is  relative to  the projected exposure (  after the last 
500 mg induction dose. 
In the pi[INVESTIGATOR_813654], once-weekly administration of 50, 150, or 270 mg/kg/dose PRA023 
via IV  injection to pregnant rabbits on gestation days (GDs) 7 and 14 was well tolerated. No 
PRA023 -related mortality, clinical observations, or effects on mean body weight gain, mean 
body weight, food consumption, or cesarean  section parameters were observed during the period 
of organogenesis (GD7 through 19). No PRA023 -related fetal external, visceral, or skeletal 
CCI
CCI
CCI
CCI
CCI
CCI
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 29 of 94 variations  or malformations were observed. The maternal and the fetal NOAELs are  
(Cmax of  and AUC 0-inf of  The exposure margins, 
based on C max and AUC 0-inf, at the NOAEL are  respectively, relative to the 
projected clinical exposures after the last [ADDRESS_1133805] 
range of human or monkey tissues. There was no PRA023- related cytokine release in in vitro 
human PBMC or whole blood cytokine release assays (soluble and plate-bound formats), nor in 
monkeys during the 6- week repeat -dose toxicity study. PRA023 did not cause CDC, ADCC, or 
ADCP  of target expressing cells in  in vitro  Fc effector function assays.  
1.4 Previous Human Experience 
A single and multiple ascending dose Phase 1 study of PRA023 in healthy volunteers has been  
complete d. In this study, doses ranging from 5 mg to 1000 mg given as a single dose or three 
multiple doses given once every two weeks  were  evaluated  (Study PR200-101).  
A total of 69 healthy subjects completed the dosing phase, 46 subjects in single ascending dose 
(SAD) phase (35 subjects received active PRA023 and 11 subjects received placebo) and 23 in 
the multiple ascending dose (MAD) phase (17 subjects received PRA023 and 6 subjects received 
placebo ) in Study PR200-101. In the SAD phase, doses of PRA023 tested were 5 mg, 25 mg, 
100 mg, 300 mg, 600 mg, and 1000 mg given as a single IV infusion. In the MAD phase, doses of PRA023 tested were 50 mg, 200 mg, and 500 mg given as IV infusion every 2 weeks for a 
total of 3 doses. No clinically significant treatment- related adverse events were reported , and no 
clinically significant laboratory abnormalities, vital signs, or ECGs were noted with PRA023, at 
doses up to 1000 mg as a single dose and 500 mg as multiple doses. The study drug was well -
tolerated, and no subjects met the study stoppi[INVESTIGATOR_3418]. 
1.4.1 Pharmacokinetic Res ults (PR200 -101 Healthy Volunteer Study)  
PK data from the PR200-101 study indicate that the exposure to serum PRA023 increased in a greater than dose-proportional manner following the administration of single and multiple 
PRA023 doses as IV infusions at doses of < 100 mg; the exposure increases at doses of ≥ 100 mg were dose-proportionate. This observation is consistent with target mediated drug disposition 
(TMDD) at lower doses (< 100 mg). The half-life of PRA023 after [ADDRESS_1133806] described by a 2 -compartment model 
with linear elimination. Demographic variables (including sex, age, race, and body size related variables) and laboratory clinical variables (including hematological, urine , and chemical 
variables) were tested for inclusion in the model for effect on the clearance and the volume of 
distribution in the ce ntral compartment. None of these variables were identified as significant 
covariates on the two PK parameters evaluated.  The results of these analyses are presented in 
the Investigator’s Brochure for PRA023. Briefly, evaluation of the model relative to observed 
CCI
CCI
CCI
CCI
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133807] the observed PRA023 concentrations and was suitable to be used to simulate PRA023 
concentrations.  
1.4.2 Safety Results  
Study PR200-101 has been  completed. There were no deaths, SAEs, severe AEs, or subjects who 
had a reduction in dose or discontinued from the study due to AEs during Study PR200-101. 
Additionally, there were no clinically significant laboratory abnormalities, vital signs, or ECGs.  
In the S AD, treatment- emergent AEs that occurred in ≥ 2 subjects dosed with PRA023 
(regardless of dose) were: headache (5 subjects [14%] in PRA023 and [ADDRESS_1133808] [9%] on 
placebo), followed by [CONTACT_29429] (2 subjects [6%] on PRA023, 0 on placebo), back pain (2 subjects 
[6%] on PRA023, 0 on placebo), and cough (2 subjects [6%] on PRA023, 0 on placebo). All 
other AEs were reported in no more than [ADDRESS_1133809]. There was 1 event of headache that was 
assessed as related to placebo that was moderate in severity. The only other AE that was assessed 
as related to PRA023 (600 mg) was somnolence, mild in severity.    
In the MAD portion of the study, treatment- emergent AEs that occurred in ≥ 2 subjects dosed 
with PRA023 (regardless of dose) were: catheter site bruise (3 subjects [18%]  on PRA023, 2 
[33%] on placebo), followed by [CONTACT_818612] (2 subjects [12%] on PRA023, 1[17%] on 
placebo), and infusion site extravasation (2 subjects [12%] on PRA023, 0 on placebo). All other 
AEs were reported in no more than [ADDRESS_1133810]. All AEs that were assessed as related to study drug 
were mild in severity. Of the AEs assessed as related to study drug by [CONTACT_737], diarrhea 
was reported in 2 subjects ([ADDRESS_1133811] on placebo) and all other 
AEs (dizziness [PRA02 3 200 mg], headache [placebo], and somnolence [PRA023 50 mg]) were 
reported in [ADDRESS_1133812]. 
For the ongoing Phase 2 studies PR200-102 ARTEMIS-UC and PR200-103 APOLLO- CD (this 
protocol), ongoing review of unblinded efficacy and safety data by [CONTACT_818613] (DMC) has resulted in the committee’s recommendation to continue the 
study. Subjects from the ARTEMIS -UC study have been dosed for up to 10 months (i.e., either 
10 months of PRA023 or 3 months of placebo followed by 7 months of PRA023) and subjects 
from this study (the  APOLLO -CD study , which is open- label)  have been dosed for up to 9 
months of PRA023 as of the date of this protocol amendment. 
1.5 Dose Rationale  
PRA023 is a humanized monoclonal antibody that binds human TL1A. I t is expected that the 
ultimate goal of PRA023 treatment in humans will be to saturate the TL1A target in 
intestinal/colonic tissue of disease patients to obtain optimal efficacy. Based on the emerging 
safety, tolerability, pharmacodynamic (PD), and PK data from the PR200- 101 study and 
modeling, the dos ing regimen  selected for induction in this study is PRA023 1000 mg on Week 
0/Day 1 followed by 500 mg on Weeks 2, 6, and 10, administered intravenously. This regimen is 
expected to lead to optimal target modulation and confer pharmacologic efficacy. T he NOAEL 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133813] 500 mg induction dose (i.e., highest predicted AUC due to 
accumulation with repeat dosing) in this dosing regimen. 
A population PK model was built based on the available data from Study PR200-101. The model 
was adequate to predict and simulate PRA023 exposure and no significant demographic or laboratory covariates were identified. Based  on the population PK model, assuming the PK is 
similar between healthy volunteers and moderate to severe UC patients, the dosing regimen of PRA023 1000 mg on Week 0/Day 1 followed by 500 mg on Weeks 2, 6, and 10 is expected to lead to a C
max (mean ± SD) o f  and an AUC 0-672hr of  
after the last [ADDRESS_1133814] concentration obtained during the PR200-103 clinical dosing regimen. This level of 
exposure has already been evaluated in the 1000 mg SAD cohort of the healthy volunteer study 
(Study PR200-101).  As stated, t he highest exposure during the PR200-[ADDRESS_1133815] 500 mg induction dose due to 
accumulation with repeat dosing. The predicted AUC is expected to be approximately equivalent (within 10%) to that after the Phase 1 dosing regimen of 500 mg every other week.   
From an induction efficacy pe rspective, assuming clearance of free soluble TL1A ( sTL1A ) from 
the gut will translate into efficacy, a physiologically based pharmacokinetic model was used to 
predict the impact of various dosing regimen of PRA023 on the level of sTL1A in normal and 
disease states in the central compartment (serum) and gut. The model predicts that the proposed 
induction regimen will lead to sTL1A levels of lower than healthy volunteers  if the production 
level of sTL1A in the colon is as high as 60 -fold. 
After the 12 -week i nduction, subjects who are in response will continue in the open- label 
extension randomized to 2 maintenance regimens. The maintenance regimen of 250 mg Q4W is 
selected to maintain the sTL1A level to below that of healthy volunteers if the production of sTL1A in the colon is up to 20X and the 100 mg Q4W regimen is selected to maintain the 
sTL1A level to below that of healthy volunteers if the production of sTL1A in the colon is up to 10X. 
1.6 Overall Benefit/Risk Assessment  
It is the hope that PRA023 will provi de comparable or better efficacy than the currently approved  
biologic therapy, with an alternative and novel mechanism of action. There has been no safety signal identified based on nonclinical toxicity studies, safety analyses from normal healthy voluntee rs treated with up to [ADDRESS_1133816] ion, and infections.  
Since there is limited experience with use of PRA023, several steps will be taken to ensure that the benefit-risk relationship of study participation continues to be favorable throughout the study. In addition to ongoing safety monitoring of data throughout this study, a formal analysis is 
CCI
CCI
CCI
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133817] completed 12 weeks of treatment or early terminated from the 
study. Lastly, the study will be conducted under the aegis of an independent Data Monitoring Committee ( DMC) which will perform safety and efficacy assessments at regularly scheduled 
times as well as on an ad hoc basis if needed, throughout this and a randomized, placebo -controlled  
study in UC (PR200-102). 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 33 of 94 2 STUDY OBJECTIVES  
2.1 Primary Objective 
• To evaluate t he safety and tolerability of PRA023 following 12 -weeks of induction therapy  
• To assess t he proportion of subjects with endoscopic improvement (decrease in simple 
endoscopy score for Crohn’s disease [ SES- CD] ≥ 50%  from Baseline ) at Week 12  
2.2 Secondary Objectives  
• To assess the proportion of subjects with clinical remission ( Crohn’s disease activity 
index [ CDAI ] < 150) at Week 12 
• To assess the proportion of subjects with endoscopy and clinical improvement (decrease 
in SES- CD ≥ 50% AND reduction in CDAI ≥ 100 points  from Baseline) at Week 12  
• To assess the proportion of subjects with biomarker and clinical improvement (decrease 
in hsCRP or fecal calprotectin ≥ 50%  from Baseline, among subjects with at least one 
elevated biomarker at Baseline,  AND reduction in CDAI ≥ 100 points from Baseline) at 
Week 12 
• To assess the proportion of subjects with normalization of hsCRP < ULN ), among 
subjects with elevated concentrations at Baseline,  at Week 12  
• To assess the proportion of subjects with normalization of fecal calprotectin (fecal 
calprotectin < ULN ), among subjects with elevated concentrations at Baseline, at Week 12  
• To assess the proportion of subjects with clinical improvement (reduction in CDAI ≥  100 
points from Baseline ) at Week 12  
• To assess the proportion of subjects with two component patient-reported outcome 
(PRO- 2) remission (average daily abdominal pain score ≤ 1 point and average daily stool 
frequency ≤ 3 points with abdominal pain and stool frequency no worse than Baseline ) 
Week 12  
• To assess the change in SES -CD score from Baseline to Week 12 
• To assess the PK of PRA023 
• To assess the immunogenicity of PRA023 
2.3 Exploratory Objectives 
• To assess t he change in CDAI and component scores over time 
• To assess the effects of PRA023  on tissue and serum PD markers, including TL1A 
concentrations, endoscopic healing index ( EHI), fecal calprotectin, and hsCRP in all 
subjects over time  
• To assess t he change in SES- CD at Week 50 from Baseline  
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 34 of 94 • To characterize the change in PDAI score from Baseline to Week 12 , Week 28 and 
Week  50 
• To characterize the effect of PRA023 for improvement and remission of enterocutaneous 
and/or perianal fistula during the Induction Period ( IP) and Open -Label Extension ( OLE ) 
• To assess a ll secondary endpoints at Week 50 
• To assess the change in GHAS and RHI from Baseline to Week 12 and Week 50 
• To assess t he proportion of subjects with histologic response and histologic remission  at 
Week 12 and Week 50 
• To assess t he change in PRO-2 over time 
• To assess t he change in extraintestinal manifestations over t ime 
• To assess long -term safety, tolerability, and efficacy of PRA023 
 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 35 of 94 3 STUDY ENDPOINTS  
The following will be measured for the evaluation of the study endpoints. 
3.1 Primary Endpoints 
• Safety and tolerability: the proportion of subjects reporting AEs, SAEs, AEs leading to 
discontinuation, and markedly abnormal laboratory values 
• The proportion of subjects with endoscopic improvement, as defined by [CONTACT_818614]- CD ≥ 50% from Baseline  at Week 12   
3.2 Secondary Endpoints  
• The proportion of subjects in clinical remission (CDAI < 150) at Week 12 
• The proportion of subjects with endoscopic and clinical improvement , as defined by 
[CONTACT_818615] ≥ 50% AND reduction in CDAI ≥ 100 points from Baseline at Week  12 
• The proportion of subjects with both biomarker and clinical improvement (decrease in hsCRP OR fecal calprotectin ≥ 50%  from Baseline, among subjects with at least one 
elevated biomarker at Baseline,  AND reduction in CDAI ≥ 100 points  from Baseline) at 
Week 12 
• The proportion of subjects with normalization of hsCRP (as defined by [CONTACT_53832] < ULN ), 
among subjects with elevated concentrations at Baseline,  at Week 12  
• The proportion of subjects with normalization of fecal calprotectin (as defined by [CONTACT_818603] < ULN), among subjects with elevated concentrations at Baseline, at 
Week  12 
• The proportion of subjects in clinical response, as defined by [CONTACT_818604] ≥ 100 points from Baseline at Week 12  
• The proportion of subjects with PRO- 2 remission ( defined as average daily abdominal 
pain score ≤ 1 point and average daily stool frequency ≤ 3 points with abdominal pain 
and stool frequency no worse than Baseline) at Week 12  
• Change in SES- CD score at Week 12 from Baseline  
• Descriptive summaries of PK and immunogenicity of PRA023 
• Proportion of subjects developi[INVESTIGATOR_84065]-drug antibody ( ADA) and neutralizing antibody ( Nab) 
3.3 Exploratory Endpoints  
• Change in CDAI and components from Baseline over time 
• Change in PD markers including TL1A concentrations , EHI, fecal calprotectin, and 
hsCRP over time  
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 36 of 94 • Change in SES- CD from Baseline at Week 50 
• Change in PDAI from Baseline over time 
• Proportion of subjects with improvement or remission of enterocutaneous and/or perianal fistula at Week 12 and Week 50 
• Change in GHAS and RHI from Baseline to Week 12 and Week 50 
• The proportion of subjects with GHAS histologic score ≤ 4 at Week 12 and Week 50 
• The proportion of subjects with Robarts histologic score < 5 at Week 12 and Week 50 
• The proportion of subjects with GHAS histologic remission, defined as no neutrophils in the epi[INVESTIGATOR_818584] 0, at Week 12 and Week 50 
• The proportion of subjects with Robarts histologic remission (<  3) at Week 12 and 
Week  50 
• Change in PRO-2 over time 
• The proportion of subjects with extraintestinal manifestation through Week 5 0 
• The long- term safety, tolerability, and efficacy of PRA023 through Week 134 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 37 of 94 4 INVESTIGATIONAL PLAN  
4.1 Study Design  
This is a multi- center, open -label, proof of concept study designed to assess the safety, tolerability,  
and preliminary efficacy of PRA023 following 12 weeks of induction therapy in subj ects with 
CD. This study will be conducted under the aegis of a D MC and will commence following the 
demonstration of an acceptable safety profile of PRA023 at a dose of ≥ 500 mg in the multiple 
ascending dose study in normal healthy volunteers (Study PR200-101). 
The study has 4 periods (Screening, IP, OLE , and FU Period). An ileocolonoscopy must be 
performed during the Screening Visit between 28 to 10 days prior to the Week 0 /Day 1 . 
Following the Screening Period, approximately 50 eligible subjects with moderately to severely 
active CD will enter the IP to receive PRA023 1000 mg on Week 0/Day 1, followed by [ADDRESS_1133818] dose. 
Response at Week 12 will be defined as reduction from Baseline in CDAI of ≥  [ADDRESS_1133819] the option to enter OLE , 
where they will be randomized to either 250 mg IV Q4W or 100 mg IV Q4W until Week 134. Subjects will continue in OLE until they progress, withdraw from the study, study termination, 
or Week 134.  
The study may be amended by [CONTACT_818616] 134 weeks based on 
emerging safety data.    
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 38 of 94 4.1.1 Study Schema  
The overall schema for the study is noted below. 
Figure  1 Study Schema  
 
 
 
Q4W = every 4 weeks ; ® = Randomization  
Number of Subjects 
Approximately [ADDRESS_1133820] Participation Duration  
Time permitted from screening to dosing:  Up to [ADDRESS_1133821] participation   
 Induction : 12 weeks  
 Open -Label Extension : Based on emerging safety data , until Week 13 4  
 Follow -Up: [ADDRESS_1133822] Numbering and Randomization  
[IP_ADDRESS] Screening Numbers 
All s ubjects will be assigned a unique six- digit screening  number. The first four digits will be the 
site number and the last t wo digits will be a number sequentially assigned by [CONTACT_779]. This 
number will be used to identify the subjects on all screening documents and during their study 
participation . 

PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 39 of 94 [IP_ADDRESS] Randomization Numbers  
Subjects who meet the required criteria for PRA023 treatment will be assigned a subject 
randomization number. Since this is an open -label study, there is no formal randomization per se; 
the randomization number will be captured in the IRT to denote that the subject has been 
allocated to PRA023 treatment and to ensure that appropriate number of subjects have been enrolled in the study. Responders who are re- randomized in OLE will retain their original 
randomization numbers. 
4.2 Study Subjects/Population  
All subjects must meet the study inclusion and exclusion criteria outlined below in order to 
participate in the study. All subjects must also meet other site -specific criteria (e.g., screening 
and on-study criteria established by [CONTACT_818617]- 19 mitigation) in order to participate in 
the study. These criteria will be amended by [CONTACT_779](s) as situation changes during the course of 
the study and should be documented by [CONTACT_818618] a site-specific COVID -19 risk mitigation plan .  
If absolutely necessary , for extenuating circumstances related to COVID -19, study activi ties may 
also be deviated as described by [CONTACT_818619] -19 mitigation plan.  
4.2.1 Inclusion/Exclusion Criteria  
[IP_ADDRESS] Inclusion Criteria  
Subjects are required to meet the following criteria in order to be included in the study: 
1. Male or female ≥  [ADDRESS_1133823] had a diagnosis of CD (confirmed by [CONTACT_235127] + histology) at least [ADDRESS_1133824] be confirmed at time of screening colonoscopy. Note that mention of “chronic inflammation” or “Crohn’s disease” or equivalent on histology report is acceptable. 
3. Moderately to severely active CD as defined by [CONTACT_818605] ≥ 220 and ≤ 450. 
4. SES- CD score (per central reading) ≥ 6 if ileocolonic or colonic disease; or ≥ [ADDRESS_1133825] one of the following criteria:  
a) In the past,  had an inadequate response to one or more  of the following treatments:  
• Oral prednisone ≥ 40 mg/day (or equivalent) or budesonide ≥ 9 mg/day or equivalent 
or beclomethasone ≥ 5 mg/day  for at least 2 weeks  
• Corticosteroid dependence as defined by [CONTACT_813676] < 10 mg/day of 
prednisone equivalent (i.e., had a flare of disease) within 3 months of starting therapy, 
or if relapse occurs within 3 months of stoppi[INVESTIGATOR_818592]023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 40 of 94 • Immunosuppressants (azathioprine ≥ 2 mg/kg/day or 6- mercaptopurine ≥ 1.0 mg/kg/day, 
[or documentation of a thera peutic concentration of 6-thioguanine nucleotide] or 
methotrexate ≥ 15 mg/week) for at least 8 weeks . Note: a  lower dosage of 6- MP or 
AZA is acceptable if local guidelines specify a different treatment regimen  (which 
would need be documented in the source  document) 
• An approved anti- TNF agent at an approved labeled dose for at least 8 weeks  
• An approved anti-integrin (e.g., vedolizumab ) at an approved labeled dose for at least 
8 weeks 
• An approved anti- IL-12/23 (e.g., ustekinumab) at an approved labeled dose for at least 
8 weeks 
OR 
b) Had been intolerant to one or more of the above mentioned treatments (e.g ., unable 
to achieve doses or treatment durations because of dose- limiting side effects 
[e.g., leukopenia, psychosis, uncontrolled diabetes, elevated liver enzymes])  
OR 
c) Currently  receiving one or more  of the following treatments:  
• Oral Prednisone ≥  10 mg/day (or equivalent) or budesonide ≥ 3 mg/day or 
beclomethasone ≥ 5 mg/day for at least 3 months 
• Immunosuppressants [azathioprine ≥ 2 mg/kg/day or 6- mercaptopurine ≥ 1.0 mg/kg/day, 
(or documentation of a therapeutic concentration of 6-thioguanine nucleotide)] for at least 8 weeks. Note: a lower dosage of 6- MP or AZA is acceptable if local guidelines 
specify a different treatment  regimen  (which would need be documented in the source 
document)
 
Notes on subjects who have had prior approved biologic therapy(ies) (e.g., anti- TNF, anti-
integrin , and/or  anti-IL-23): 
• The study will include a maximum of 70% and a minimum of approximately 50% subjects who have had prior approved biologic therapy(ies) experience. Upon reaching the maximum number of allowed biologic experienced subjects (70%), subjects who have had prior biologic experience will no longer be all owed to enter the study. Upon reaching 
the maximum number of allowed biologic-naïve subjects (approximately 50%), subjects 
who have never been exposed to a prior biologic will no longer be allowed to enter the study.
 
• Subjects cannot have had failed (no response, insufficient response, loss of response, and/or intolerance) > 4 approved biologic therapi[INVESTIGATOR_014], whether of same or different mechanism of action . 
• Subjects previously on clinical trials only (i.e. , did not receive commerc ial available 
therapy post-approval) are  not considered to have received the approved therapy for 
purpose of this inclusion criteria. 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133826] meet drug stabilization requirements, as applicable:  
a) Oral corticosteroid treatment must be  equivalent of ≤ 20 mg prednisone or ≤ 9 mg 
budesonide or beclomethasone ≤ [ADDRESS_1133827] 2 weeks prior to 
Day 1  
b) Oral aminosalicylates should be at a stable dose for at least 2 weeks prior to Day 1 
c) Azathioprine, 6- mercaptopurine, and methotrexate should be at a stable dose for at least 
4 weeks prior to  Day 1  
9. Able to provide written informed consent and understand and comply with the requirements of the study. 
[IP_ADDRESS] Exclusion Criteria  
Subjects with the following characteristics will be excluded from the study: 
Sex and Reproductive Status  
1. WOCBP and men with female partners of childbearing potential who are unwilling or unable 
to use two highly effective methods of contraception to avoid pregnancy for the entire study period and for up to [ADDRESS_1133828] on enrollment or prior to Day 1 . 
Target Disease Exceptions 
4. Diagnosis of ulcerative colitis or indeterminate c olitis . 
5. CD isolated to the stomach, duodenum, jejunum, or perianal region, without colonic and/or  
ileal involvement. 
6. Suspected or diagnosed intra- abdominal or perianal abscess at Screening . 
7. Known symptomati c stricture or stenosis not passable in endoscopy ( including pediatric 
colonoscope). 
8. Current stoma or need for colostomy or ileostomy.  
9. Previous small bowel resection with combined resected length of >  100 cm or previous 
colonic resection of >  2 segments .  
10. Currently receiving total parenteral nutrition . 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133829] a history of clinically significant drug or alcohol abuse. 
16. Concomitant illness that in the opi[INVESTIGATOR_689], is likely to require systemic glucocorticosteroid therapy during the study (e.g., moderate to severe asthma) . 
17. Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, pulmonary, cardiac, neurological, ophthalmologic, or cerebral disease. Concomitant medical conditions that in the opi[INVESTIGATOR_818585] . 
18. Subjects with a history of cancer within the last 5 years (other than non -melanoma skin  cell 
cancers cured by [CONTACT_109413]). Existing non- melanoma skin cell cancers must be removed 
prior to enrollment. Subjects with carcinoma in situ or localized cervical cancer, treated with definitive surgical intervention, are allowed . 
19. Subjects at risk  for tuberculosis (TB). Specifically, subjects with: 
a) A history of active TB  
b) Current clinical, radiographic or laboratory evidence of active TB 
c) Latent TB which was not successfully treated. Subjects with a positive TB screening test indicative of latent TB will not be eligible for the study unless active TB infection has been ruled out, and an appropriate course of intervention for latent TB has b een initiated  
at least [ADDRESS_1133830] 3 months, unless treated and resolved with antibiotics, or any chronic bacterial infection (such as chronic pyelonephritis, osteomyelitis , and bronchiectasis). 
21. Female subjects who have had a breast cancer screening that is suspi[INVESTIGATOR_109373], and in whom the possibility of malignancy cannot be reasonably excluded following additiona l clinical, laboratory , or other diagnostic evaluations. 
22. Subjects with any active infections (excluding fungal infections of nail beds) including, but 
not limited to, those that require IV  antimicrobial treatment 4 weeks or oral antimicrobial 
treatment 2 w eeks prior to randomization. Subjects with evidence of Human 
Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C infection detected during screening  are also excluded . Subjects with successfully treated H epatitis C with no 
recurrence for ≥  1 year are  allowed . Subjects with active documented or suspected COVID -
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133831] positivity 
within 2 weeks of randomization are excluded.  
23. Subjects with herpes zoster reactivation or cytomegalovirus ( CMV) that resolved less than 
[ADDRESS_1133832] Findings 
25. Positive stool Polymerase Chain Reaction (PCR) if I nvestigator deems this positivity reflects 
infection rather than colonization  or positive culture for enteric pathogens. 
26. Stool positive for Clostridium difficile  (C. difficile ) toxin. Subjects who are positive can be 
retested after the completion of a full course of treatment for C.  difficile  infection . 
27. Any of the following lab values: 
a) Hemoglobin ( Hgb) < 8.0 g/dL (80 g/L)  
b) White blood cell (WBC ) < 2,500/mm3 (2.5 x 109/L) 
c) Neutrophils < 1,000/mm3 (1 x 109/L) 
d) Platelets < 100,000/mm3 (100 x 109/L) 
e) Serum creatinine > 2 times upper limit of normal  (ULN)  
f) Serum  alanine aminotransferase ( ALT ) or aspartate aminotransferase ( AST) > [ADDRESS_1133833]  
g) Any other laboratory test results that,  in the opi[INVESTIGATOR_689], might place the 
subject at unacceptable risk for participation in this study 
Prohibited Therapi[INVESTIGATOR_13265]/or Medications  
28. Failed (no response, insufficient response, loss of response, and/or intolerance) > 4 approved 
biologi c therapi[INVESTIGATOR_014] (anti -TNF, anti- integrin, anti- IL12/23), whether of same or different 
mechanism of action. 
29. Any marketed biologic within 8 weeks for anti-TNF agents and 12 weeks for anti-integrin agents (e.g., vedolizumab) and ustekinumab prior to Day 1  or if drug level per therapeutic 
dose monitoring is greater than lower limit of detection . 
30. Any biologic immunomodulators used for CD or other conditions within 8 weeks or 5 half -
lives, whichever is longer, prior to Day 1 or if drug level per therapeutic dose  monitoring is 
greater than lower limit of detection . 
31. Rituximab within 1 year prior to Day 1 . 
32. Parenteral corticosteroids within 4 weeks or rectal administration of corticosteroids within 2 weeks prior to Day 1 . 
33. Rectal administration of 5- ASA within 2 weeks  prior to Day 1 . 
34. Tacrolimus, cyclosporine, mycophenolate mofetil (CellCept
®), immunoadsorption columns 
(such as Prosorba columns), D Penicillamine, Leflunomide, Thalidomide, chronic use of non-steroidal anti-inflammatory agents ( NSAIDs ), and use of aspi[INVESTIGATOR_248] >  81 mg/day within 
2 weeks prior to Day 1 . 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 44 of 94 35. Other investigational chemical agent within 30 days or other investigational biologic agent 
within 8 weeks or 5 half -lives (whichever is longer) of entry into the IP . 
36. Prior exposure to PRA023. 
Other Exclusion Cri teria  
37. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness .
 
38. Legal or mental incapacitation, or inability to understand and comply with the requ irements 
of the study.  
39. Known allergies, hypersensitivity, or intolerance to PRA023 or its excipi[INVESTIGATOR_840].   
4.3 Contraception Guidelines 
The I nvestigator or his/her designee will discuss with the subject the need to use two highly 
effective methods of contraception consistently and correctly according to Schedule of Study 
Assessments ( Section  6.1.1) and document such conversation in the subject’s chart. In addition, 
the Investigator or his or her designee will instruct the subject to call immediately if the selected 
contraception methods are discontinued or if pregnancy is known or suspected in the subject or the subject’s partne r. 
All women who have experienced menarche are WOCBP  unless meeting criteria for women of 
non-childbearing potential as described below . This includes women who are using an active 
method of birth control, are practicing abstinence , with same sex partner,  have undergone tubal 
ligations, or where the partner is sterile (e.g., vasectomy). 
WOCBP involved in any sexual intercourse that could lead to pregnancy will be eligible for the 
study provided they use two highly effective methods of contraception for at least [ADDRESS_1133834] dose of study drug.
 
Highly effective methods of contraception are those that, alone or in combination, result in a 
failure rate of less than 1% per year when used consistently and correctly (i.e. , perfect use) an d 
include the following:  
1. Established use of oral, inserted, injected, implanted or transdermal hormonal methods of 
contraception is allowed provided the subject plans to remain on the same treatment 
throughout the entire study and has been using that hormonal contraceptive for an 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 45 of 94 adequate period of time to ensure effectiveness  
2. Correctly placed copper- containing intrauterine device  (IUD)  
3. Male condom or female condom used WITH a spermicide (i.e., foam, gel, film, cream, or 
suppository). For countries where spermicide is not available and condoms alone are 
considered an effective method of contraception, at the Investigator’s discretion, the use of condom alone without spermicide is acceptable and sufficient to meet this requirement. 
4. Male sterilization with doc umented absence of sperm in the post -vasectomy  ejaculate  
5. Bilateral tubal  ligation/bilateral salpi[INVESTIGATOR_818593] 
(provided that occlusion has been confirmed in accordance with the device’s label)  
6. Female s who meet  the criteria  for non-childbearing potential, as described below: 
Woman of non -childbearing potential must meet at least one of the following criteria : 
• Have  had surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral 
salpi[INVESTIGATOR_1656])  
• Have medically confirmed ovarian failure 
• Female s who are postmenopausal with amenorrhea without an alternative medical cause 
for at least [ADDRESS_1133835] follicle stimulating hormone ( FSH) 
serum levels consistent with postmenopausal status as per investigator judgment  
4.4 Concomitant Treatments and Restrictions  
4.4.1 Prior and Concomitant Medications  
Any prior or ongoing CD medications, including corticosteroids, immunosuppressives (AZA, 6-MP, and MTX), anti- TNFs , anti-integrins, and anti- IL-12/[ADDRESS_1133836] will be 
recorded on the eCRF . 
All concomitant medication(s) and treatment(s) administered/taken during the study must  be 
recorded with indication, dose, and start and stop dates of administration. All subjects will be questioned about concomitant medication at each site visit.  
Medication(s) administered/taken following the first dose of PRA023 will be documented as concomitant medication(s).  
4.4.2 Permitted  Medications  with Restrictions  
Subjects will be allowed to use the following medications as detailed below:  
• A stable dose of 5- ASA for at least 2 weeks prior to Day 1  and throughout the IP 
• A stable dose of oral corticosteroids (prednisone ≤ 20 mg/day or equivalent) for CD for at 
least [ADDRESS_1133837]’s condition allows (see Section  4.4.4). 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 46 of 94 • A stable dose of oral budesonide (≤  9 mg/day or equivalent) or beclomethasone ≤ 5 
mg/day for at least [ADDRESS_1133838]’s condition allows (see Section  4.4.4). 
• A stable  dose of immunosuppressants ( AZA, 6- MP, or methotrexate) for  4 weeks prior to 
Day 1  and during the IP . 
4.4.3 Prohibited Medications  
• Any marketed biologic therapy throughout the study 
• IV corticosteroid for treatment of CD  during the IP  
• Oral corticosteroid (p rednisone >  20 mg/day or equivalent ) for the treatment of CD 
during the IP   
• Oral budesonide >  9 mg/day or equivalent or beclomethasone > 5 mg/day during 
the IP  
• Any per rectal therapy including enema (e.g., 5- ASA, budesonide, corticosteroid) during 
IP, other than that required for endoscopy preparation during the IP .  
• Systemic t acrolimus, systemic cyclosporine, oral mycophenolate mofetil ( MMF ), 
immunoadsorption columns (such as Prosorba columns), D-penicillamine, leflunomide, 
Thalidomide, purified medicinal probiotics throughout the study 
• Chronic use of NSAIDs or aspi[INVESTIGATOR_248] >  100 mg/day during the IP  
• Any investigational drug other than the study medication throughout the study 
4.4.4 Corticosteroid and Budesonide Tapering Schedule During Open -Label 
Period  
After the completion of all Week 12 assessments, background oral corticosteroid and/or budesonide therapy should be tapered if the subject is in remission (as defined in Section  6.4) or 
has a satisfactory response to treatment per I nvestigator.  
For prednisone  or equivalent , dose should be reduced at a rate of 2.5 mg (daily dose) of prednisone 
or equivalent per week ; although the I nvestigator may use an alternative regimen if preferred . For 
budesonide  and beclomethasone , tapering schedule per site protocol with goal of completing the 
tapering regimen within 8 weeks.  
4.4.5 Other Restricted Medications  
Due to the risk of infection, vaccination of subjects with any live vaccine is contraindicated during the treatment period of the study (i.e., at any time after randomization into the IP ), as is 
the administration of LIVE oral polio vaccine to household contacts. The Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (CDC ACIP) recommends that subjects should not be administered a live virus vaccinatio n for at least 3 months  
after immunosuppressive therapy. Therefore, study subjects should not be administered a live 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133839] permanently discontinues PRA023 treatment and withdraws from the 
study, subjects will no longer need to abstain from the medications that were prohibited. Howev er, biologic treatment(s) should not be initiated for [ADDRESS_1133840] dose of 
PRA023 without discussion with the Sponsor due to the long half- life (t
1/2) of PRA023.  
Subjects are free to withdraw from the study at any time at their own request, or they may be withdrawn at any time at the discretion of the I nvestigator or Sponsor. If a subject requires 
initiation of a new therapy for CD, the subject should be withdrawn from the study and appropriate treatment should be administered at the discretion o f the Investigator. 
4.[ADDRESS_1133841] be made to determine the reason(s) why a subject fails to return for the necessary visits or is discontinued from the study. This information and date must be recorded on the appropriate eCRF  and on the Termination Sheet. Subjects MUS T discontinue from the study 
for any of the following reasons: 
• The subject decides that it is in his/her best interest. It is fully understood that all subjects volunteer for the study and that they may withdraw their consent to continue in the study at an y time.  
• Any AE, laboratory abnormality, or change in medical condition which, in the opi[INVESTIGATOR_689], indicates that continued participation in the study is not in the best interest of the subject.  
o For potential drug induced liver injury (DILI), timely confirmation of initial liver -
related laboratory abnormalities should be performed. Potential drug induced liver injury is defined as: 
 ALT/AST elevation >[ADDRESS_1133842], AND  
 Total bilirubin >[ADDRESS_1133843], without initial findings of cholestasis (elevated serum 
alkaline phosphatase), AND 
 No other immediately apparent possible cause of increased ALT/AST and total bilirubin, such as viral hepatitis A, B, or C; preexisting or acute liver disease; or other drug capable of causing the observed injury 
o Subjects with suspected DILI should be discontinued from the study 
• Persistent n on-compliance of the subject   
• Pregnancy 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 48 of 94 • Use of any investigational drug therapy for CD excluding study treatment 
• Treatment with biologic therapy for CD  
The Investigator must notify the Medical  Monitor by [CONTACT_818620]. The date when the subject is withdrawn and 
the reason for discontinuation must be recorded in the eCRF . If a subject is “lost to follow -up” 
(fails to  return for study visits), a reasonable effort should be made to contact [CONTACT_813691]. This information must be documented in the eCRF . 
If a subject is withdrawn from the study early (regardless of the cause) all of the end -of-study 
evaluations should be performed at the time of withdrawal, and the subject followed for [ADDRESS_1133844] dose of PRA023, if possible, due to the long t 1/2 of PRA023. 
It is agreed that, for reasonable cause, either the Investigator or the Sponsor, Prometheus, may 
terminate this study.  
4.6 Modification of Study Drug Dosing  
Investigators should reference the Investigator’s Brochure  (IB)  for PRA023  and use their best 
clinical judgment to determine the continuation of dosing during the study. PRA023 doses 
should be withheld until after the resolution of clinically significant infections. Reference 
Section 5.4 for dose modification recommendations related to infusion reaction. 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133845]  
5.1 Dosing Form  and Preparation 
PRA023 concentrate for  solution for infusion will be provid ed as a single -dose glass v ial 
containing 500 mg of PRA023 at 60 mg/mL dose strength. PRA023 will be packaged in a box 
containing [ADDRESS_1133846](s)  or designee will be  
preparing study drug for infusion. Detailed study drug preparation and handling instructions will 
be provided to the investigational pharmacist in the Pharmacy Manual.  
5.[ADDRESS_1133847] be stored in a secure, lockable area in 36oF - 46oF (2oC - 8oC) controlled 
storage conditio n prior to use . All study drug must continue to be stored in a secure, lockable 
area until it is returned to the Sponsor or designee or destroyed upon approval by [CONTACT_95346]. 
5.[ADDRESS_1133848]  also provide a written explanation for any missing study drug. 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133849] 2 infusions (Week 0/Day 1 and Week 2) should be 1* 
hour and subsequent infusions should be 30 minutes ( Table  2 and Table  3).  
Some of the major safety concerns associated with immunogenicity are anaphylaxis, cytokine release syndrome, “infusion reactions”, and non- acute reactions such as delayed hypersensitivity.  
The information below is provided as guidance to assess anaphylaxis, but the clinical judgment of the Investigator should be considered as well. 
Anaphylaxis is a serious, acute allergic reaction characterized by [CONTACT_401360]. Signs 
and symptoms of anaphylaxis may include: 
• Generalized hives, pruritis/itching, flushing, sw ollen  lips/tongue/uvula  
• Symptoms of respi[INVESTIGATOR_7798] (e.g. , dyspnea, wheeze/bronchospasm, stridor, 
reduced peak expi[INVESTIGATOR_10229], hypoxemia) 
• Reduced blood pressure (systolic blood pressure of less than 90 mm Hg or greater than 30% decrease from baseline) or associated symptoms of end -organ dysfunction 
(e.g., hypotonia [collapse], syncope, incontinence) 
• Persistent gastrointestinal symptoms (e.g. , crampy abdominal pain, vomiting) 
If a subject experiences anaphylaxis, PRA023 administration should be discontinued immediately and permanently. If a subject experiences symptoms that may be attributed to hypersensitivity reaction or delayed hypersensitivity (e.g., fever, rash, arthralgia, myalgia, hematuria, proteinuria, serositis, central nervous system complications, or hemolytic anemia), PRA023 infusion should be stopped. 
In the event that symptoms are mild or minor in severity, at the discretion of the Investigator, the 
infusion may be restarted at a slower rate if symptoms are resolved within 1 hour a fter stoppi[INVESTIGATOR_65084]. If symptoms return, PRA023  should be discontinued immediately and permanently. 
In the event that there is an infusion interruption, the entire duration of PRA023 infusion, from the initial start of infusion, to the completion of infusion, should not exceed 24 hours of PRA023 dilution. Subjects will receive appropriate treatment at the discretion of the Investigator. 
                                            
* 2 hours for subjects in Czech Republic  
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133850] cannot be performed, the I nvestigator will 
document the reason for this and any corrective and preventive actions that he or she has taken to ensure that normal processes are adhered to as soon as possible. The Sponsor or designee will be 
informed of these incidents in a timely fashion. 
6.1 Study Visit Procedures  
A written, signed informed consent form (ICF) must be obtained from each subject prior to 
performing any study procedure. Medical/surgical history, medication record (prior and concomitant  
medications and therapy), and a physical examination including vitals will be obtained for all subjects at the Screening Visit. A series of laboratory and diagnostic/clinical tests and evaluations  
will be performed. At least two visits to the clinical facility may be necessary to complete all 
screening procedures, including an ileocolonoscopy. The ileocolonoscopy should be performed 
after all other eligibility criteria , including CDAI during Screening, have been met and within 
28-10 days of Day 1 to allow SES- CD score calculation.  
Subjects may be re-screened one time at the discretion of the S ponsor if they fail their initial 
screening.  
After Week 0/ Day 1 , all subjects will be evaluated frequently through a series of physical 
examinations, and laboratory tests and assessments for safety and efficacy as described in the Schedule of Study Assessm ents tables ( Section  6.1.1).  
 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 52 of 94 6.1.1 Schedule of Study Assessments  
 Schedule of Study Assessments – Screening Period  
Procedure  Study Visit  
Screening  NOTES 
Screening duration is up to 35  days ( 5 weeks)  
Eligibility Assessments  
Informed Consent  X  
Inclusion/Exclusion Criteria  X  
Medical and Surgical History  X  
Smoking History  X  
Prior and Current Concomitant Medications X  
Safety Assessments 
Complete Physical Examination  X  
Targeted Physical Examination    
Vital Signs  X Height at Screening Visit [ADDRESS_1133851] Training on Electronic Diary (eDiary) 
Completion X  
Issue eDiary to Subject  X Remind subjects to record in their eDiary daily  
Ileocolonoscopy with Biopsy  X Ileocolonoscopy should be performed between 28 to 10 days 
prior to the Week 0/Day [ADDRESS_1133852] been met.  
Laboratory Tests  
Pharmacogenomics (Buccal Swab and Blood)  X In case of DNA extraction failure, additional sample should be collected for CDx testing.  
Stool PCR or Culture X Can be performed centrally or locally. Ova and parasite 
examination should also be performed based on local guidelines. 
C. difficile  PCR/ Toxin  X Can be performed centrally or locally . 
Fecal calprotectin  X To be performed during screening, prior to Week 0/Day [ADDRESS_1133853] if negative result available within 90 days of screening.  
Human Immunodeficiency Virus (HIV) X Per local regulations. To be assayed locally  or centrally per 
country/regional regulations . Confirmation  and documentation of 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 53 of 94 Procedure  Study Visit  
Screening  NOTES 
Screening duration is up to 35  days ( 5 weeks)  
a negative HIV test result within 3 months (except for subjects 
in Czech Republic) prior to screening will be accepted.  
Serum Pregnancy Test (WOCBP only)  X  
 
PRA023 
Protocol PR200- 103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 54 of 94 
 Schedule of Study Assessments – Induction Period 
 Study Visit  NOTES  
Study Week  0 1 2 6 10 12 Early 
Termination  
Study Day  1 8 15 43 71 85 
Visit window (days)  0 ±1 ±3 ±3 ±3 ±3  
Procedure         
Eligibility Confirmation  X        
Randomization X       Via IRT system  
Complete Physical Examination       X X  
Targeted Physical Examination  X  X X X    
Vital Signs  X X X X X X X Heart rate, temperature, blood pressure; Take pre -dose (no more than 30 
minutes pre -infusion), end of infusion, and end of observation period.  
Weight X X X X X X X Needed for CDAI assessment  
ECG X     X X  
Adverse Events Assessment  X X X X X X X  
Concomitant Medication  X X X X X X X  
Efficacy Assessments  
Ileocolonoscopy with Biopsy       X X Ileocolonoscopy to be performed within [ADDRESS_1133854] in their eDiary daily  
CDAI Assessment  X X X X X X X  
PDAI  X     X X  
Fistula Drainage Assessment  X  X X X X X  
IBDQ X   X  X X  
Laboratory Testing 
CBC X X X X X X X  
Chemistry Panel  X  X X  X X  
Fasting Lipid Panel  X     X X  
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 55 of 94  Study Visit  NOTES 
Study Week  0 1 2 6 10 12 Early 
Termination  
Study Day  1 8 15 43 71 85 
Visit window (days)  0 ±1 ±3 ±3 ±3 ±[ADDRESS_1133855] (WOCBP only)  X   X  X X  
Pharmacokinetics Xa X Xb Xb Xa X X a.  The PK sample at Week 0/Day [ADDRESS_1133856] be taken pre -
dose, immediately following the end of infusion (within 30  minutes), 
and [ADDRESS_1133857] be taken pre -dose 
(within 30  minutes prior to dosing).  
Immunogenicity Xa  Xa Xa  X X a. To be taken pre -infusion 
Biomarkers  
Biomarkers X  X X X X X Serum at all visits; additional whole blood at W eeks 0, 6 and 12  
Soluble TL1A  X  X X X X X  
hsCRP X X X X X X X  
Fecal Calprotectin  X   X  X X  
Infusion  X  X X X   Include date, start  and stop time, volume infused, and length of the IV 
infusion. 
Infusion observation period at Week 0/Day 1 and Week 2 will be 1 hour 
(2 hours for subjects in Czech Republic); 30 minutes for all subsequent 
infusions thereafter.  
 
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 56 of 94 
 Schedule of Study Assessments – Open -Label Extension Period  Up to Week 50 
 Study Visit  NOTES  
Visit windows are as follows: +14 day window for Week 14 visit, 
±7 day window from Week 18 to Week 24 visit s, and ±14 day 
window if >Week 24  
 
Study Week  14 18 26 34 42 50 
Early 
Termination  Infusion Visits 
Q4W 
(excluding Office 
Visits)   Study Day  99 127 183 239 295 351 
Visit window (days)  +14 ±7 ±14 ±14 ±14 ±14  ±7/±[ADDRESS_1133858] into IRT for OLE  X         
Complete Physical Examination       X X   
Targeted Physical Examination  X X X X X     
Vital Signs  X X X X X X X X Heart rate, temperature, blood pressure; Take pre -dose (no more 
than 30 minutes pre -infusion) and end of infusion  
ECG      X X   
Weight X X X X X X X  Needed for CDAI assessment  
Adverse Events Assessment  X X X X X X X X  
Concomitant Medication  X X X X X X X X  
Efficacy Assessments  
Review eDiary  Data from Subjects  X X X X X X X  Remind subjects to record in their eDiary daily  
CDAI Assessment  X X X X X X X   
PDAI    X   X X   
Fistula Drainage Assessment  X X X X X X X   
Ileocolonoscopy with Biopsy    Xa,b   X X  Ileocolonoscopy to be performed between 14  and 8 days before 
Week 26 and Week 50 visits or within 1 week after  Week 5 0 
visit or ET visit 
aIf the investigator feels there is a contraindication, this Week 26 
endoscopy could be considered optional .  
bBiopsies are optional.  
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 57 of 94  Study Visit  NOTES 
Visit windows are as follows: +14 day window for Week 14 visit, 
±7 day window from Week 18 to Week 24 visit s, and ±14 day 
window if >Week 24  
 
Study Week  14 18 26 34 42 50 
Early 
Termination  Infusion Visits 
Q4W 
(excluding Office 
Visits)   Study Day  99 127 183 239 295 351 
Visit window (days)  +14 ±7 ±14 ±14 ±14 ±14  ±7/±[ADDRESS_1133859] (WOCBP only)  X X X X X X X X Pregnancy testing must be done once a month  
Pharmacokineticsc Xa Xa Xa  Xa Xb X  a. To be taken pre -infusion. 
b. To be taken pre -infusion or at the same time as other laboratory 
tests for early termination.. 
Immunogenicity  Xa Xa  Xa Xa X  a. To be taken pre -infusion 
Biomarkers  
Biomarkers X X X X X X X  Serum at all visits; additional whole blood at Week 50  
Soluble TL1A  X X X X X X X   
hsCRP X X X X X X X   
Fecal Calprotectin    X   X X   
Infusion X X X X X X  X Include date, start and stop time, volume infused, and length of 
the IV infusion.  
Infusion observation period will be 30 minutes 
  
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 58 of 94 
 Schedule of Study Assessments – Open -Label Extension Period (After Week 50)  
 Study Visit  NOTES  
Visit windows are  ±14 days  
Study Week  Quarterly * 
Office Visits  Early 
Termination  Infusion 
Visits 
(excluding 
Office Visits)  * Weeks 62, 74, 86, 98, 110, 122, 134  
Procedure     
Complete Physical Examination  Xa X  a. Yearly  
Targeted Physical Examination  X    
Vital Signs  Xa Xa X Heart rate, temperature, blood pressure; Take  pre-dose (no more than 30 minutes 
pre-infusion) and end of infusion  
a. Weight needed  
Adverse Events Assessment  X X X  
Concomitant Medication  X X X  
Efficacy Assessments  
Review Diary Data from Subjects  X   Paper diaries may be used  
CDAI  Assessment  X X   
PDAI   Xa Xa  a. To be performed on every subject every [ADDRESS_1133860] (WOCBP only)   X X X Pregnancy testing must be done once a month prior to dosing  
Urinalysis Xa. X  a. Every 6 months  
Pharmacokinetics Xa Xb  a. To be taken pre -infusion; every 6 months  
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 59 of 94  Study Visit  NOTES  
Visit windows are  ±14 days  
Study Week  Quarterly * 
Office Visits  Early 
Termination  Infusion 
Visits 
(excluding 
Office Visits)  * Weeks 62, 74, 86, 98, 110, 122, 134  
Procedure     
b. To be taken at the same time as other laboratory tests for early termination  
Immunogenicity Xa X  a To be taken pre -infusion; every 6 months  
Biomarkers 
hsCRP Xa X  a. Every 6 months  
Fecal Calprotectin  Xa X  a. Every 6 months  
Serum biomarkers  Xa X  a. Every 6 months; additional whole blood sample at Week 98 
Infusion X  X Infusions should be at Q4 week interval  
Include date, start and stop time, volume infused, and length of the IV infusion  
Infusion observation period will be 30 minutes  
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133861] Dosing Period  
Visit window  (days)  ±7 ±7 ±[ADDRESS_1133862] (WOCBP only)  X X X 
Pharmacokinetics  X X X 
Immunogenicity  X X X 
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133863] 
safety  and/or exacerbation assessments. The additional procedures are at the discretion of the 
Investigator. The details of these unscheduled procedures will be recorded in the source documents and entered into the eCRF s. 
6.3 Safety Assessment Description  
6.3.1 Medical History, Physical Examination , Height and Weight  
Medical history, including CD history, will be collected at the Screening V isit. 
The Investigator will perform a complete physical examination at the Screening V isit and at the 
visits specified in the schedule of study procedures ( Section  6.1.1). The complete physical 
examination must include the following: 
• General appearance  
• Hair and skin 
• Lymph nodes 
• Head  
• Eyes  
• Ears, nose, and throat 
• Neck  
• Respi[INVESTIGATOR_696]  
• Cardiovascular  
• Abdominal 
• Musculoskeletal  
• Mental status  
• Neurological 
Unless otherwise indicated, following screening visit, physical examinations should be targeted 
(symptom directed). Complete and targeted physical examinations are to be performed at specified visits  according to the schedule of study procedures ( Section  6.1.1).  
Height and weight will be measured without the subject wearing shoes. Height (inches or 
centimeters) will be measured and recorded at the screening visit only and weight (lbs  or kg) 
will be measured and recorded at specified visits  (Section  6.1.1).  
6.3.2 Vital Signs  
Vital signs to be assessed are heart rate, respi[INVESTIGATOR_697], body temperature, and resting blood 
pressure. The body position (sitting or supi[INVESTIGATOR_050]) should be recorded. Approved medical devices 
may be used to record these parameters.  
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133864] x-ray (posterior- anterior and late ral views are recommended , however, local  guidelines 
should be followed) with no evidence of current, active TB or previous inactive TB, general 
infections, heart failure or malignancy is to be taken at screening or within the [ADDRESS_1133865] be 
located and available in the source  documentation. 
6.3.4 Electrocardiogram  (ECG)  
A standard 12- lead ECG for all subjects  will be performed at Screening a nd at the subsequent 
visits  specified in the  schedule of study procedures ( Section  6.1.1).  Original  ECGs with interval 
printouts and rhythm strip run at 25 mm/sec must be provided as source documentation. 
Automatically calculated QT and QTc intervals will be reviewed and checked for gross 
inaccuracies by [CONTACT_415144]. If the automatically calculated QT 
or QTc interv als are greater than [ADDRESS_1133866]’s medical background should be examined closely for risk factors that may have contributed to the event, including genotypi[INVESTIGATOR_818594], if appropriate. 
Any sign of arrhythmia should be noted. During treatment, any indication of QT prolongation or 
Torsade de Pointes, a polymorphic ventricular tachyarrhythmia that appears on the ECG as 
continuous twisting of the vector of the QRS complex around the isoelectric baseline, must be 
recorded as an adverse event and reported to the Medical Monitor.  
The decision to continue the treatment of any subject with prolonged QT or QTc interval must be 
discussed and agreed up on by [CONTACT_82171]. All such subjects, 
including subjects with cardiac arrhythmias, should be monitored closely. If appropriate, ECG 
monitoring should be performed until the QT and QTc interval and waveform morphology have 
returned to normal. If the prolongation or abnormal rhythm persists, the Medical Monitor must 
be contact[INVESTIGATOR_530].  
6.3.[ADDRESS_1133867] 
operating procedure ( SOP) of the testing facility, for the following: 
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 63 of 94 Hematology  Chemistry  
• Hemoglobin  
• Hematocrit  
• Total and differential leukocyte count 
• Red blood cell count (with indices) 
• Platelet count  • Blood Urea Nitrogen (BUN)/urea  
• Bilirubin (total and direct)  
• Uric acid  
• Alkaline phosphatase 
• Aspartate aminotransferase (AST)  
• Alanine aminotransferase (ALT)  
• Albumin  
• Sodium 
• Potassium  
• Chloride 
• Carbon dioxide/bicarbonate 
• Calcium  
• Phosphorus (inorganic)/phosphate  
• Total protein  
• Glucose 
• Lactate dehydrogenase (LDH)  
• Creatinine  
• Creatine kinase ( CK)**  
• Gamma -glutamyl transferase (GGT)  
• Lipid panel (total cholesterol, LDL, HDL and 
VLDL fractions and triglycerides)***  Urinalysis  
• pH 
• Specific gravity  
• Protein*  
• Glucose 
• Ketones 
• Bilirubin  
• Blood* 
• Nitrite*  
• Urobilinogen 
• Leukocyte esterase*  
  Serology  Other Tests  
• HBsAg  
• HBcAb  
• HIV 
• HCV  • Follicle stimulating hormone (FSH) for 
postmenopausal females only**** 
• QuantiFERON- TB 
• Serum /urine  pregnancy test (for female subjects 
only)  
  
* If urinalysis is positive for protein, blood, nitrite and/or leukocyte esterase, a microscopic examination 
(for red blood  cells, white blood cells, bacteria, casts, and epi[INVESTIGATOR_1663]) will be performed.  
** CK-MB reflex test (or Troponin 1) may be performed if CK is elevated.  
***Fasting; refer to schedule of study procedure s (Section  6.1.1 ) for fasting sample collection timepoints.  
****If needed . 
 
The Investigator must review the screening visit laboratory results for all the measured analytes 
for each subject prior to Week 0/ Day [ADDRESS_1133868] 
would be eligible if re- tested.  
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 64 of 94 All subjects with laboratory tests containing clinically significant abnormal values are to be 
followed regularly until the values return to normal ranges; until a valid reason, other than study drug- related AE, is  identified; or until further follow -up is deemed medically unnecessary. 
6.3.6 Stool Evaluation  
[IP_ADDRESS] Stool Culture  
A stool PCR or culture (per central laboratory or local laboratory availability) is to be performed 
at the screening visit only and can be performed centrally or locally at the Investigator’s 
discretion. Subjects will be provided with instructions for stool sample collection at home and 
will be required to submit the stool sample to th e site for testing. Ova and parasite examination, 
if applicable, should be performed based on local guidelines. 
[IP_ADDRESS] Screening for Clostridium  Difficile  
Highly sensitive screening tests, with high negative predictive value, should be employed in 
evaluating subjects for eligibility for the study. The detection of C. difficile by [CONTACT_818621]  [stool  culture followed  by [CONTACT_818622]] is considered  the gold standard for the 
diagnosis of the colonization or infection with pathogenic C.  difficile . Comparable 
sensitivity may be achieved by [CONTACT_401350] C. difficile toxin A and B and/or glutamate dehydrogenase (GDH) antigen on a card. Use of the card for point of c are screening is 
encouraged where permitted by [CONTACT_1295]. Molecular techniques such as polymerase chain reaction (PCR) for detection of toxin RNA are also acceptable alternatives.   
Subjects who are positive at Screening Visit can be retested after the completion of a full course of treatment for C.  difficile  infection . 
Refer to the Central Laboratory Manual for further guidance and instruction for C. difficile 
screening  if sent for central testing . If using the central lab, as the C. diff icile PCR may be the 
screening test , a positive PCR test result with a negative toxin result may reflect infection or 
colonization, and the I nvestigator should decide whether PCR positivity reflects infection , in 
which case, treatment should be administered . Sites  should follow the guidance and instructions 
from the local laboratory  if tested locally . 
6.4 Efficacy Assessment Description  
The SES- CD will be used to evaluate disease activity for the primary endpoint. The SES- CD and 
CDAI scores will be used to evaluate disease activity for the secondary endpoints. The SES- CD 
is a validated endoscopic score that is used to describe il eocolonoscopic findings in CD. SES- CD 
assesses the size of mucosal ulcers, the ulcerative surface, the endoscopic extension , and the 
presence of stenosis ( Daperno 2004, Moskovitz 2007). 
For the current study, the following definitions will apply:  
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 65 of 94 • Endoscopic Improvement – a decrease in SES -CD of ≥  50% from Baseline  
• Clinical Re mission  – CDAI <  150 
• Clinical Response – a reduction in CDAI ≥  100 points from Baseline  
• Biomarker and Clinical Composite Improvement – a decrease in hsCRP or fecal 
calprotectin ≥  50% from Baseline and reduction in CDAI ≥  100 points from Baseline  
6.4.1 Ileocolonoscopy with Biopsy  
[IP_ADDRESS] Ileocolonoscopy and SES- CD Score  
An ileocolonoscopy with biopsy should be performed during Screening and Visit Week 12/ET and Week 5 0/ET and annual ly thereafter  with whatever cancer surveillance technique is 
recommended as per local guidelines if subject has colonic involvement. The endoscopy during Screening should be performed within 28-10 days of Week 0/Day [ADDRESS_1133869]’s chart. The findings of the ileocolonoscopy, including local 
grading of SES-CD score should be completed at the end of the procedure. 
The endoscopic variables will be evaluated in 5 predefined ileocolonic segments:  
• Ileum - include the full extent for which it is examined. Do not  include the ileocecal 
valve or an ileocolonic anastomosis 
• Right colon - include the ileocecal valve, the cecum, and the ascending colon to the 
hepatic flexure  
• Transverse colon - between the hepatic and the splenic flexures 
• Descending colon - from the sple nic flexure to the rectosigmoid junction  
• Rectum - distal to the rectosigmoid junction  
The 4 endoscopic variables (each to be scored from 0 to 3 points) to be evaluated are (see Appendix 16.1):  
• Ulcers - scored according to size (diameter 0.1 - 0.5 cm, 0.5 - 2 cm, or > 2 cm) 
• Proportion of the surface covered by [CONTACT_818623] (< 10%, 10 - 30%, or  > 30%)  
• Proport ion of affected surface with any other lesions according to extent (< 50%, 50 - 75 %, 
or > 7 5%) 
• Stenosis (single or multiple, and whether the colonoscopy could pass through the narrow lumen) 
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 66 of 94 A study specific video capture kit, which includes the Endoscopy Video Instructions Manual and 
other Quick Reference materials, and a detailed Biopsy Procedural Manual will be provided by [CONTACT_941] C entral Reader vendor. 
[IP_ADDRESS] Biopsy  
During each of the ileocolonoscopi[INVESTIGATOR_014], at least 3 biopsy samples should be obtained from each of the 5 ileocolonic segments (rectum, descending colon/sigmoid, transverse colon, ascending colon, or ileum). The biopsies should be collected in the vicinity of any lesion or ulcerated ar ea, 
at the edge of the ulcerated area if possible. If no lesions were present in the segment, biopsies should be collected from random sites within the segment. Two (2) of the 3 biopsy specimens from each segment should be placed into the formalin-fixed bottles pre -filled with 10% neutral 
buffered formalin and the 3
rd of the biopsy specimens from each segment should be placed into 
the RNAlater bottles pre -filled with RNAlater solution.  
All biopsy samples will be sent to the central laboratory for the study and processed by a designated central pathology site for histological scoring. 
6.4.2 Crohn’s Disease Activity Index (CDAI) Score  
Subjects will use an eDiary  in order to record their CD symptoms on a daily basis. e Diary data 
will be assessed at the clinic from screening until the end of PRA023 treatment. Subjects will 
record the following information: 
• Number of soft/liquid stools each day 
• Daily rating of abdominal pain 
• Daily rating of general well -being 
• Daily fever  
• Daily use of anti- diarrheal medications  
The information extracted will be used for calculation of CDAI score taking into account the 
data recorded over the last 7 days prior to each study visit. If there are less than 7 available days 
reported prior to the study visit, the average will be taken from the limited available data unless 
there is no eDiary /paper diary  data reported within  7 days. Note that if there is less than 5 days of 
eDiary /paper diary  data prior to the baseline, then the subject  cannot be enrolled into the study. 
In case where there are not at least  [ADDRESS_1133870] endoscopy are not considered 
evaluable.   
In order to encourage consistent diary recording, subjects should enter diary data continuously throughout the study. Instructions for completing the eDiary /paper diary  will be provided to 
subjects at screening and reviewed at subsequent visits.  
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 67 of 94 All other elements of the CDAI not captured in the eD iary/paper diary  (Appendix 16.2) should 
be assessed by [CONTACT_818624]. The eDiaries or paper diaries and CDAI 
score worksheets will be source documents for this study. 
6.4.3 Perianal Disease Activity Index  (PDAI)  
The PDAI will be used to evaluate severity of perianal disease. The PDAI incorpora tes 5 items: 
discharge, pain, restriction of sexual activity, type of perianal disease, and degree of induration. 
Each category is graded on a 5 -point Likert scale ranging from no symptoms (score of 0) to 
severe symptoms (score of 4). Scores can range from  0 - 20, with higher scores indicating more 
severe perianal disease ( Irvine 1995 ). See Appendix 16.3 for  additional details.  
6.4.4 Fistula Drainage Assessment 
Severity of enterocutaneous and perianal disease will be assessed using the Fistula Drainage 
Assessment. Fistulas will be classified as either (1) open and actively draining or (2) closed, based on the Investigator’s physical evaluation of the subject: a fistula is open if the Investigator 
can express purulent material from the fistula with the application of gentle pressure  (Present 
1999) . Improvement is defined as a reduction ≥50% from baseline in the number of draining 
fistulas observed at 2 or more consecutive visits (at least 21 days apart). Remission is defined as the absence of any draining fistulas at 2 consecutive visits (at least 21 days apart).  
6.4.5 Quality of Life (QoL)  
Subjects will be asked to complete the Inflammatory Bowel Disease Questionnaire (IBDQ) at 
visits specified in Section  6.1.1 to measure disease specific quality of life (QoL) . The 
questionnaires completed by [CONTACT_818625]. 
The IBDQ is a self -administered 32- item questionnaire that evaluates QoL across 4 dimensions: 
(1) Bowel – symptoms related to primary bowel disturbance, (2) Systemic symptoms, (3) Emotional function, and (4) Social function. The response to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is 
computed as the sum of the responses to the individual IBDQ questions. The total score can 
range between 32 to 224 with higher scores indicating a better QoL ( Guyatt 1989 ). 
6.5 Pharmacodynamic s 
Serum biomarkers will be measured to determine the expression of pro -inflammatory cytokines 
and other soluble biomarkers that may correlate with CD disease activity. Blood samples for PD  
are to be drawn at the time points specified in the protocol (see Section  6.1.1). The actual date 
and time (24- hour clock time) of each sample will be recorded. Instructions for the handling of 
the PD samples will be provided in the Laboratory Manual. 
Evaluations of pharmacodynamics may include, but are not limited to, the following: 
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 68 of 94 Cytokines  Stool  
• Soluble TL1A  • Fecal calprotectin  
  
Biomarkers   
• Endoscopic healing index (EHI)  
• hsCRP  
• mRNA   
Any residual serum, following completion of analysis, will be stored frozen at -20°C or colder at 
the testing facility. Additional cytokines  or other biomarkers may also be evaluated based on 
emerging data  from the study for up to [ADDRESS_1133871] at the time points specified  in the protocol (see Section  6.1.1 ). Blood samples for PK analysis of 
PRA023 concentrations will be analyzed  using a validated assay method by [CONTACT_23801]. The PK blood samples will be obtained according to the study flowchart. The actual date and time (24- hour clock time) of each sample will be recorded. 
Instructions for the handling of the PK  samples will be provided in the Laboratory Manual. 
Changes in the timing or addition of time points for any planned study assessments must be documented and approved by [CONTACT_818626], but will not constitute a protocol amendment. The I RB/IEC will be 
informed of any safety issues that require alteration of the safety monitoring scheme or amendment of the ICF. PK analysis will be performed as outlined in the PK section of the Statistical A nalysis P lan (SAP) . 
6.7 Immunogenicity (Anti -Drug Antibody)  
Antibodies to PRA023  will be evaluated in blood samples collected from all subjects at the time 
points specified in the protocol (see Section  6.1.1). The detection and characterization of 
antibodies to PRA023 will be performed using a validated assay method by [CONTACT_56834]’ s designee.  Instructions for the handling of ADA samples will be provided in the 
Laboratory Manual.  
Blood samples will be screened for antibodies binding to PRA023 and the titer of confirmed 
positive samples will be reported. If confirmed positive, a ntibodies may be further characterized 
and/or evaluated for their ability to neutralize the activity of PRA023.  Other analyses may be 
performed to verify the stability of antibodies to PRA023  and/or further characterize the 
immunogenicity of PRA023. 
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133872]’s response to study treatment, su sceptibility to, and 
severity and progression of disease. Variable response to study treatment may be due to genetic 
determinants that impact drug absorption, distribution, metabolism, and excretion; mechanism of 
action of the drug; disease etiology; and/or molecular subtype of the disease being treated. Therefore, a 4 mL whole blood and buccal (cheek) swab samples for DNA isolation will be 
collected from subjects at the  Screening V isit for an assessment of pharmacogenomics (i.e., CDx 
assessment) . In the event of DNA extraction failure, a replacement genetic blood and/or buccal 
sample may be requested from the subject  during the study. 
After collection, the samples are to be shipped to the Sponsor and/or the central laboratory. 
Instructions for the handling of pharmacogenomic samples will be provided in the Laboratory Manual . The DNA samples  will be stored  in a secure storage space with adequate measures to 
protect confidentiality. Each stored sample will be identified only by [CONTACT_813697].  
6.9 Potential Future Research  
Blood, biopsy, and DNA samples will be stored for up to 5 years after study completion 
(potential for storage and duration of storage may depend on local guidelines) , after which all the 
samples will be destroyed .  Blood and biopsy samples may be tested for levels of biomarker and 
other pharmacodynamic markers.  DNA samples may be used in the future for various evaluations, including, but not limited to, the potential association between g enotype and drug 
absorption, distribution, metabolism, and excretion; mechanism of action of the drug; disease etiology; and/or molecular subtype of the disease. 
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 70 of 94 7 ADVERSE EVENTS AND S ERIOUS ADVERSE EVENT S 
The following definitions of terms are guided by [CONTACT_818627] U.S. Code of Federal Regulations [21 CFR 312.32] and are included herein. 
An adverse event (AE) is any untoward medical occurrence associated with the us e of a drug in 
humans, whether or not considered drug related. AEs include, but are not limited to:  
• Any symptom or condition not previously reported by [CONTACT_423] (medical history). 
• An exacerbation of a pre-existing symptom or condition. 
• A significant inc rease in frequency or intensity of a pre-existing epi[INVESTIGATOR_89274]. 
• A drug interaction. 
• A condition first detected or diagnosed after study drug administration even though it 
may have been present prior to the start of the study. 
An AE does not include: 
• Medical or surgical procedures (e.g., surgery, endoscopy, tooth extraction, or blood transfusion); the condition that leads to the procedure is an adverse event (e.g ., bleeding 
esophageal varices, dental caries).  
• Overdose of either study drug or c oncurrent medication without any clinical signs or 
symptoms.  
All identified A Es after signing of informed consent until [ADDRESS_1133873] 
be recorded and described on the appropriate non-serious or serious AE page of the eCRF . If 
known, the diagnosis of the underlying illness or disorder should be recorded, rather than 
individual symptoms. 
Suspected adverse reaction means any AE  for which there is a reasonable possibility that the 
drug caused the AE. For the purposes of safety reporting, ‘reasonable possibility’ means there is 
evidence to suggest a causal relationship between the drug and the AE . A suspected adverse 
reaction implies a lesser degree of certainty about causality than adverse reaction, which means 
any AE  caused by a drug. 
An adverse reaction is any AE  caused by a drug. Adverse reactions are a subset of all suspected 
adverse reactions for which there is reason to conclude that the drug caused the event.  
An AE  or suspected adverse reaction is considered “serious” if, in the v iew of either the 
Investigator or sponsor, it results in any of the following outcomes: 
• Death  
• A life -threatening adverse event 
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 71 of 94 • Inpatient hospi[INVESTIGATOR_1081] 
• A persistent or significant incapacity or substantial disru ption of the ability to conduct 
normal life functions  
• A congenital anomaly/birth defect 
• Disability/incapacity that is persistent and significant  
Important medical events that may not result in death, be life -threatening, or require hospi[INVESTIGATOR_763974], based upon appropriate medical judgment, they may jeopardize 
the subject and may require medical or surgical intervention to prevent one of the outcomes listed  
in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse. 
An AE  or suspected adverse reaction is considered “life -threatening” if, in the view of either the 
Investigator or sponsor, its occurrence places the subject or subject at immediate risk of death. It 
does not include an AE  or suspected adverse reaction that, had it occurred in a more severe form , 
might have caused death. 
An AE  or suspected adverse reaction is considered ‘unexpected’ if it is not listed in the 
Investigator ’s Brochure or is not listed at the specificity or severity that has been observed; or, if 
an Investigator ’s Brochure is not re quired or available, is not consistent with the risk information 
described in the general investigational plan or elsewhere in the current application. For example,  
under this definition, hepatic necrosis would be unexpected (by [CONTACT_14213]) if the 
Investigator’s Brochure referred only to elevated hepatic enzymes or hepatitis. Similarly, cerebral  
thromboembolism and cerebral vasculitis would be unexpected (by [CONTACT_14214]) 
if the Investigator’s Brochure listed only cerebral v ascular accidents. ‘Unexpected,’ as used in 
this definition, also refers to AEs  or suspected adverse reactions that are mentioned in the 
Investigator’s Brochure as occurring with a class of drugs or as anticipated from the pharmacological properties of the drug, but are not specifically mentioned as occurring with the 
particular drug under investigation. 
The Sponsor will determine the expectedness of serious adverse reactions and report all suspected,  
unexpected serious adverse reactions (S[LOCATION_003]Rs) according to statutory requirements.  
7.[ADDRESS_1133874] administered the study drug as “pre-
treatment- emergent” AEs . Any pre- treatment- emergent event will be  recorded as an AE but will 
be clearly documented as pre- treatment emergent event  in the data listings . 
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 72 of 94 7.2 Laboratory Abnormalities as Adverse Events 
Many laboratory abnormalities observed during the course of a study will be included under a 
reported AE  describing a clinical syndrome ( e.g., elevated BUN and creatinine in the setting of 
an AE  of renal failure, or decreased hemoglobin in a case of bleeding esophageal varices). In 
such cases, the laboratory abnormality itself (e.g., elevated creatinine in a setting of renal failure) does not need to be recorded as an AE . However, isolated laboratory abnormalities should be 
reported as AEs if they are considered to be clinically significant by [CONTACT_737]. Criteria for 
a “clinically significant” laboratory abnormality are:  
a) A laboratory abnormality that leads to a dose-limiting toxicity (e.g., an abnormality that 
results in study drug dose reduction, suspension or discontinuation), or 
b) A laboratory abnormality that results in any therapeutic intervention (i.e., concomitant medication or th erapy), or  
c) Other laboratory abnormality judged by [CONTACT_818628] (e.g., significant fall in hemoglobin not requiring transfusion) 
For laboratory abnormalities that do not meet the above criteria but are outside of normal range 
(e.g., < or > normal reference range), the Investigator should indicate whether the value is clinically significant (CS) or not clinically significant (NCS) for the subject.  
7.3 Grading/ Severity of Adverse Events 
The Investigator must define the severity of each AE using the NCI ’s CTCAE Version 5.[ADDRESS_1133875] appropriate according to her/his medical judgment.  
 Severity of Adverse Events  
Grade  Clinical Description of Severity  
1 Mild; asymptomatic or mild symptoms; clinical or diagnostic  observations only;  intervention not indicated.  
2 Moderate; minimal, local or noninvasive intervention indicated;  limiting age-appropriate instrumental ADL*.  
3 Severe or medically significant but not immediately life -threatening; hospi[INVESTIGATOR_24599]; disabling; limiting  self care ADL**.  
Note : An experience may be severe but may not be serious, e.g., severe headache).  
4 Life-threatening consequences; urgent intervention indicated.  
5 Death related to AE.  
A Semi -colon indicates ‘or’ within the description of the grade.  
Note: Activities of Daily Living (ADL): 
*Instrumental ADL refer to preparing meals, shoppi[INVESTIGATOR_3112], using the telephone, managing money, etc.  
**Self care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedrid den. 
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 73 of 94 7.4 Relationship of Adverse Events  
7.4.1 Relationship of Adverse Events to Study Drug Administration  
The Investigator will determine if there is a reasonable causal relationship between the study drug  
and an AE or not. The Investigator will use her/his best medical judgment and consider all relevant  
factors ( e.g., temporal relationship, location of the event, the subject’s relevant medical history, 
concomitant therapi[INVESTIGATOR_014], and concurrent conditions) to determine the relationship of the AE to the study drug. The Investigator will define the relationship of an AE to the study drug by [CONTACT_118238]: 
Related : There is a reasonable possibility that there is a causal relationship between the 
study drug and the AE.  
Not Related : There is not a reasonable possibility that there is  a causal relationship between 
the study drug and the AE.  
The term “reasonable causal relationship” means there are facts or arguments to suggest a causal relationship (International Conference on Harmonisation (ICH) E2A).  
7.4.2 Relationship of Adverse Events to Study Procedures  
Relationship (causality) to study procedures should be determined for all pre- treatment -emergent 
events and AEs. The relationship should be assessed as Related if the Investigator considers that 
there is reasonable possibility that an ev ent is due to a study procedure. Otherwise, the 
relationship should be assessed as Not Related.  
7.[ADDRESS_1133876] be documented and 
reported. 
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 74 of 94 7.5.2 Investigator Reporting of a Serious Adverse Event  
In agreeing to the provisions of this protocol, the Investigator accepts all legal responsibilities for 
prompt notification of serious adverse events ( SAEs ) to  The 
Investigator (or designee) is required to complete the SAE page in the eCRF enabling 
transmission to  using the electronic data capture (EDC) system. In the event  
EDC transmis sion is not possible, (e.g., there are access or system problems), then  the 
Investigator (or designee) must report the  SAE  to  by [CONTACT_395456] a completed paper SAE form to: 
Fax:  
Email:  
All SAEs  must be reported to  within  24 hours after the Investigator 
recognizes/classifies the event as a SAE .  
The initial SAE report should include at a minimum: subject number, a narrative descriptio n of 
the event, and an assessment by [CONTACT_813699]. The initial SAE report received from the site should be as complete as 
possible. A complete follow -up SAE report must be submitted when information not available at 
the time of the initial report becomes available.  The Sponsor (or designee) may request SAE 
follow -up information. Copi[INVESTIGATOR_1672] (e.g., ECGs, laboratory 
tests, discharge summary, postmortem results) should be sent to the addressee, if requested.  
The Investigator must receive acknowledgement by  [CONTACT_818629]. In the event that the Sponsor or designee permits an alternat e 
delegate, the Investigator and staff will be notified and provided the alternate’s contact [CONTACT_3031].  
The Investigator is responsible for continuing to report to the  any new or 
relevant  follow-up information that he/she learns about the SAE . 
7.5.3 Investigator Reporting of a Pregnancy  
Investigator (or designee) should notify  of all pregnancies occurring 
after start of study drug and [ADDRESS_1133877] dose in enrolled female subjects or the female 
partner of male subjects.  
If a pregnancy occurs, a Pregnancy Report Form should be completed by [CONTACT_737] (or designee) and submitted to  via fax to , or by [CONTACT_20143] 
.com within [ADDRESS_1133878]. A determination regarding study 
drug discontinuation will be made for male subjects with a partner pregnancy based on risks 
involved by [CONTACT_11219]/or Sponsor. 
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133879] interfered 
with the effectiveness of a contraceptive medication.  
The outcome of all pregnancies (spontaneous miscarriage, elective termination, normal birth, or 
congenital abnormality) must be followed up and documented even if the subject was 
discontinued from the study. Female partners of male subjects are asked to sign a separate partner pregnancy informed consent form in order to collect pertinent personal and medical 
information regarding th e status and outcome of the pregnancy. 
All reports of congenital abnormalities/birth defects are considered SAEs and should be reported 
per Section  7.5.2. Spontaneous miscarriages should also be reported and handled as SAEs. 
Elective abortions without complications should not be handled as AEs unless they were 
therapeutic abortions . The medical  reason ( e.g., fetal disease) for therapeutic abortion will be 
reported as an SAE . 
7.[ADDRESS_1133880]’s safety or until the event stab ilizes or resolves. If resolved, a resolution date should be 
documented on the eCRF  or reported to Sponsor or designee if the eCRF s have been collected. 
The Investigator is responsible to ensure that follow- up includes any supplemental investigations 
as may be indicated to elucidate the nature and/or causality of the AE . This may include 
additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals as is practical.  
7.[ADDRESS_1133881] -Study Serious Adverse Events  
Investigators are not obligated to actively follow subjects after the completion of the study. However, if the Investigator becomes aware of an SAE , he/she should notify  
 if such events are attributable to the study drug. The notification to  
 of a post-study SAE  by [CONTACT_415173] 24 hours of becoming aware 
of the SAE . 
CCI
CCI
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 76 of 94 7.9 IRB/IEC Notification of Serious Adverse Events  
The Investiga tor is responsible for promptly notifying her/his IRB/IEC of all SAEs , including 
any follow-up information, occurring at her/his site and any SAE  regulatory report, including 
any follow- up reports that he/she receives from the Sponsor or designee. 
7.10 Health Authority Safety Reports  
Prometheus or its representatives will submit a safety report to appropriate regulatory agencies, for all suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) and any other applicable SAEs to regulatory authorities in accordance with national regulations in the countries where the study is conducted. S[LOCATION_003]Rs will be submitted to the regulatory authorities as expedited report within [ADDRESS_1133882] be submitted 
to the appropri ate IRB/IEC according to local regulations and guidelines. Documentation of the 
submission to the IRB/IEC must be retained for each safety report.  
7.11 Data Monitoring Committee (DMC)  
Prometheus will establish an independent DMC for PRA023 to oversee the benefit- risk profile  in 
IBD and safety across the entire program . The DMC will review safety data at periodic intervals 
from this and all other PRA023 studies conducted by [CONTACT_813702]. Members of the 
DMC will not be allowed to participate as Investigators in any of the PRA023 studies.  
A charter, which will include a detailed description of the scope and the extent of its responsibilities  
and procedures, will be implemented prior to any data review. The charter will specify how the 
data will be provided to the committee member (e.g., blinded, unblinded, grouped or not, etc.) 
for review. These documents (charter, open and closed meeting minutes, etc.) will be considered 
part of the study documentation, but not of this protocol. The DMC will review data within its 
general remit to oversee subject safety for the PR200 program and provide recommendations and 
guidance to the Sponsor in accordance with the procedures stated in its charter.  
A formal DMC monitoring meeting will occur prior  to the commencement of this  study, where 
the DMC will assess all available safety data from the normal healthy volunteer study (Study 
PR200-101). This study will commence following the demonstration of acceptable safety profile 
of PRA023 at a dose of ≥ 500 mg in multiple ascending dose study in Study PR200-101. 
All Investigators, responsible IRB/IECs, and applicable regulatory agencies will be informed of 
any decisions made by [CONTACT_818630]. The Investigators will inform the 
subjects of such actions and the protocol and ICF will be revised, as appropriate. 
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 77 of 94 8 ASSESSMENT OF STUDY VARIABLES  
The data will be analyzed by [CONTACT_813704] (e.g., a contract research organization [CRO]).  
8.[ADDRESS_1133883] randomization number by [CONTACT_818631] 0/Day [ADDRESS_1133884] s, which will provide a statistical power of 80% to test 
against the null hypothesis of endoscopic improvement rate of 12%, at 1- sided significance level 
of 0.025, assuming the endoscopic improvement rate for PRA023 is 27%.  
The null hypothesis of an endos copic improvement (decrease in SES -CD ≥ 50%) rate of 12% is 
based on a meta -analysis estimate of the upper limit of 95% CI of the observed placebo rate 
(95% CI) of 9.5% (7.1, 11.9) from  multiple modern- era CD clinical trials with centrally read 
endoscopy and similar eligibility criteria (Table  7). 
 Placebo Endoscopic Response Rates in Recent CD Clinical Trials  
Clinical Trial  N Placebo Endoscopic Response Rate (%)  
Feagan  et al.  [ADDRESS_1133885] to safety observations . Monitoring of AEs, physical 
examinations, vital signs, ECGs, safety and tolerability monitoring evaluations, clinical 
laboratory evaluations, and special procedures are detailed in Section  6.3. 
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133886] one dose of PRA023 
will be included in the safety analysis, which will be primarily descriptive.  
The safety variables will be: 
• Hematology, chemistry, and urinalysis 
• Vital signs  
• ECG parameters  
• Physical examination 
• AEs and SAEs  
o AEs of special interest: infections, acute infusion reaction  (within 1 hour of completion  
of infusion), and peri-infusion reaction (within 24 hours of completion of infusion) 
o AEs in subjects who are ADA positive  
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133887] descriptive summary statistics: number of 
observations, arithmetic mean, standard deviation (SD), coefficient of variation (CV), minimum, 
median , and maximum. The geometric mean (GM) will be reported for PK and PD variables 
where appropriate. Categorical data will be summarized as number and percentage of subjects. 
Shift tables will be provided, where appropriate.  
9.1 Analysis Populations 
9.1.1 Safety Analysis Set (SAS) Population  
All subjects who received at least one dose of the study drug will be included in the safety 
evaluations. 
9.1.2 Full Analysis Set  (FAS) Population  
The FAS  population will be a subset of the Safety  population and will include all subjects who 
have been treated with PRA023 with Baseline SES- CD scores.  
9.2 Statistical Analyses  
9.2.1 Demographics and Baseline Characteristics  
Demographic data characteristics (height, weight, age, sex, race, and ethnic origin) will be listed by [CONTACT_818632].  
9.2.[ADDRESS_1133888] the null hypothesis of 12%, an observed placebo 
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133889] the null hypothesis of clinical remission rate of 16% (an 
observed remission rate for the placebo treated patients from multiple CD trials ( [COMPANY_013] 2021 , 
Feagan 2017, Sands 2019, Selinger 2018, Vermeire 2017 ). 
The point estimates for the primary and secondary endpoints will be calculated along with 95% 
confidence interval for FAS and by [CONTACT_818633] (CDx+ or CDx -). 
9.2.3 Evaluation of Pharmacodynamic Parameters  
The PD markers, circulating cytokine levels, will be summarized using descriptive statistics: N, 
mean , SD, min , max, median , coefficient of variation as a percent (CV %), and GM by [CONTACT_818633] . 
Any p- values that will be calculated according to the analysis plan will be interpreted in view of 
the exploratory nature of the study. 
9.2.[ADDRESS_1133890] on PRA023 exposure .  
9.2.5 Evaluation of Exploratory Parameters  
Changes from baseline in exploratory PD parameters will be computed, as appropriate. All exploratory parameters will be summarized using descriptive statistics. Graphs of change from baseline will be presented , as appropriate. 
9.2.6 Evaluation of Pharmacokinetic Parameters  
PK parameters will be comp uted, as appropriate, from the individual serum concentrations using 
a non- compartmental approach. All PK parameters will be summarized using descriptive 
statistics: N, mean, SD, min, max, median, CV %, and GM and GM CV%. Serum concentrations 
of PRA023 wil l be summarized .  
9.2.7 Evaluation of Safety Parameters  
[IP_ADDRESS] Adverse Events and Adverse Events of Special Interest  
All AEs  will be coded using most current version of Medical Dictionary for Regulatory 
Activities ( MedDRA). All reported adverse events will be assigned to the SOC and PT according 
to MedDRA. The number and percentage of subjects reporting AEs  (all, serious, related) will be 
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 81 of 94 tabulated by [CONTACT_813707]. AEs will be summarized by [CONTACT_3592]. AE s will also be 
summarized by [CONTACT_53429], seriousness, and severity. 
A treatment -emergent AE (TEAE) will be defined as an AE that began or worsened on or after 
the first treatment dose. A Es recorded prior to the first infusion of study treatment wil l be 
considered non- treatment- emergent.  
All reported A Es (treatment-emergent or not) will be listed. Only TEAEs will be summarized.  
AEs of special interest including infections, acute infusion reaction (within 1 hour of completion 
of infusion), and peri- infusion reaction (within 24 hours of completion of infusion) will be 
summarized based  on a pre -specified MedDRA list.  
AEs occurring in subjects who are considered immunogenicity positive will also be summarized.  
[IP_ADDRESS] Medical History , Chest X -ray, ECGs and Physical Examination 
Medical history , chest x -ray, ECGs , and physical examination data will be listed by [CONTACT_1130]. All 
medical history will be coded using the most current version of MedDRA. Changes in ECGs and physical examination will be described in the text of the final study report. 
[IP_ADDRESS] Clinical Laboratory  and Vital Signs  
All clinical laboratory results  and vital signs measurements, and their change from baseline, will 
be summarized by [CONTACT_349992]. 
A shift table describing out-of-normal range shifts will be provided for clinical laboratory results.  
[IP_ADDRESS] Previous  and Concomitant Medication  
All previous and concomitant medication will be listed by [CONTACT_1130]. Prior and concomitant 
medications will be coded using the most current World Health Organization – Drug Dictionary (WHO -DD).  
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133891] 
The Investigator or designee is responsible for ensuring that the study is conducted in accordance 
with the clinical protocol and is in full compliance with regulatory requirements; the basic 
principles outlined in 21 CFR Parts 50, 54, 56, and 312; ICH-guidelines for Good Clinical 
Practice as published in the Federal Register on May 9, 1997; and the Declaration of Helsinki.  
The Investigator is also responsible for protecting the rights, safety, and welfare of subjects under the Investigator’s care and for the control of study device under investigation. 
The Investigator(s) (and sub investigators) will provide the Sponsor with her/ his/their up -to-date 
scientific Curriculum Vitae (signed and dated) prior to start of the study  and when new site 
personnel are added once the study commences. 
10.[ADDRESS_1133892] Approval/ Independent 
Ethics Committee 
Regulatory appr oval will be obtained from the appropriate regulatory authority prior to initiation 
of the study protocol. 
The I nvestigator is responsible for obtaining IRB /IEC  approval for the study protocol and the 
subject informed consent form. A copy of the dated appr oval letter from the IRB/IEC  stating the 
study title, and/or study number must be provided to the Sponsor before the start of screening 
and release of supplies. A list of the names of the committee members will be obtained for the Sponsor’s and Investigator’s records.  
10.[ADDRESS_1133893] be reviewed and approved by [CONTACT_1744]/IEC  before use in the study. Each volunteer 
must sign and date this form prior to their participation in the study. A signed original consent form for each subject will be kept on file at the clinical site. A copy of the signed consent w ill be 
provided to the subject. 
10.[ADDRESS_1133894]’s health information. Confidential data may be disclosed to the Investigator and 
employees, sponsor, IRB /IEC , FDA , or other authorized representatives during the course of the 
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 83 of 94 study or when requested. Information will remain confidential and will not be used for any 
purpose other than the type of review requested. 
10.5 Protocol Modification/Amendments 
Sponsor modifications made to the experimental design, study parameters, subjec t selection , or 
any other content in the protocol will be communicated with a protocol amendment(s) to the investigator, FDA and other regulatory agencies for review and approval . All amendments will 
require IRB/IEC  review and approval prior to implementation.   
10.[ADDRESS_1133895] Access to Source Data/Documents  
Investigator will permit trial- related monitoring, audits, IRB/IEC review , and regulatory 
inspections by [CONTACT_20618]/documents. 
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133896] been recruited and completed the study as 
stated in the regulatory application (i.e., clinical trial application [CTA]) and ethics application in 
the Member State. Poor recruitment (recruiting less than the anticipated number in the CTA) by a Member State is not a reason for premature termination but is considered a normal conclusion to 
the study in that Member  State.  
11.[ADDRESS_1133897] visit (LSLV).  
 
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 85 of 94 12 DATA MANAGEMENT  
Data will be handled and processed according to C RO’s  SOPs, which are written based on the 
principles of GCP. At all times, appropriate backup copi[INVESTIGATOR_818595] d software 
files will be maintained and the information will be appropriately protected from unauthorized 
access.  
The eCRF  development will be based on the study protocol. All eCRF  data, including laboratory 
data, will be included in an integrated database. At the end of the study when the database is 
deemed clean , the integrated database will be locked (i.e., all data entry, quality control , database 
edits, medical coding, SAE reconciliation complete). The data will then be processed, evaluated, 
and stored in anonymous form in accordance with applicable data protection regulations. 
eCRF s will be kept for each subject and will document all study data. The eCRF s must be 
completed for each subject to allow the progress and results of the study to be closely followed 
by [CONTACT_11200]. 
The study monitor or designee will review the eCRF s for completeness and accuracy via Source 
Document Verification. Study written ICFs  and all study specific logs will be verified for 
completeness, accuracy , and plausibility. 
12.1 Coding of Adverse Events, Concomitant Medication, and Medical 
History  
After data entry, the A Es and medical history will be coded according to the MedDRA®. Where 
required, concomitant medication will be coded according to the WHO-DD. The versions of 
MedDRA® and WHO -DD used in the study will be specified in the data management plan (DMP).  
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 86 of 94 13 DOCUMENTATION AND ADMINISTRATIVE CONSIDERATIONS  
13.1 Recordkeepi[INVESTIGATOR_818596] (including study file, source documentation, copi[INVESTIGATOR_813660] , etc.) should be retained by [CONTACT_818634] a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least [ADDRESS_1133898] 
commercial confidential materials (patents, etc.), not to restrict publication.  
All information concerning the product subsequently generated from this study (such as patent 
applications, formulae, manufacturing processes, basic scientific data, or formulation information  
supplied to the investigator by [CONTACT_124820]) is considered 
confidential by [CONTACT_813710]. The Investigator agrees not to 
use it for other purposes without the Sponsor’s written consent. 
It is understood by [CONTACT_941] I nvestigator that the Sponsor will use the information developed in this 
clinical study in connection with the development of PRA023 and, therefore, may be disclosed as 
required to other Sponsor investigators or any appropriate international regulatory authorities. In 
order to allow for the use of information derived from this clinical study, the Investigator 
understands that he or she has an obligation to provide the Sponsor with complete test results and all data developed during this study. 
Prior to submitting the results of this study for publication or presentation, the Investigator will 
allow the Sponsor 60 days in which to review and comment upon the publication manuscript. In 
accordance w ith generally recognized principles of scientific collaboration, co authorship with 
any Sponsor personnel will be discussed and mutually agreed upon before submission of a 
manuscript to a publisher. The publication of study data may not be performed without the 
written prior approval of the Sponsor, and this approval shall not be unreasonably withheld. 
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133899] precede any proposed 
individual publication. 
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page [ADDRESS_1133900] participating in the study permitting the release 
of his/her medical records as necessary for in spection by [CONTACT_813712], 
the FDA, and/or other regulatory health authorities. 
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 89 of 94 15 REFERENCES  
[COMPANY_013], Risankizumab (SKYRIZI®) demonstrates significant improvements in clinical 
remission and endocopic response in two Phase 3 induction studies in patients with Crohn’s disease [Internet]. Illinois: [COMPANY_013] Inc.; 2021; 07 Jan [cited 2021 Feb 2]. Available from: https://news.abbvie.com/news/press- releases/risankizumab -skyrizi-demonstrates- significant -
improvements- in-clinical -remission -and-endoscopic-response- in-two-phase -3-induction -studies-
in-patients -with-crohns- disease.htm  
Ananthakrishnan AN, Kaplan GG, Ng SC. Changing Global Epi[INVESTIGATOR_818597]: Sustaining Health Care Delivery Into the 21st Century. Clin Gastroenterol Hepatol. 2020;18(6):1252-60. doi: 10.1016/j.cgh.2020.01.028. 
Bamias G, Kaltsa G, Siakavellas SI, Papaxoinis K, Zampeli E, Michopoulos S, Zouboulis-
Vafiadis I, Ladas SD. High intestinal and systemic levels of decoy receptor 3 (DcR3) and it s 
ligand TL1A in active ulcerative colitis. Clin Immunol. 2010;137(2):242-9. doi: 10.1016/j.clim.2010.07.001. 
Bamias G, Martin C, 3rd, Marini M, Hoang S, Mishina M, Ross WG, Sachedina MA, Friel CM, 
Mize J, Bickston SJ, Pi[INVESTIGATOR_229700], Wei P, Cominelli F. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol. 2003;171(9):4868-74. doi: 10.4049/jimmunol.171.9.4868. 
Banfield C, Rudin D, Bhattacharya I, Goteti K, Li G, Hassan- Zahraee M, Br own LS, Hung KE, 
Pawlak S, Lepsy C. First- in-human, randomized dose-escalation study of the safety, tolerability, 
pharmacokinetics, pharmacodynamics and immunogenicity of PF-06480605 in healthy subjects. 
Br J Clin Pharmacol. 2020;86(4):812-24. doi: 10.1111/bcp.[ZIP_CODE]. 
Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn’s disease activity 
index. National Cooperative Crohn’s Disease Study. Gastroenterology 1976; 70: 439–44.  
Cleynen I, González JR, Figueroa C, Franke A, McGovern D, Bortlík M, C rusius BJ, Vecchi M, 
Artieda M, Szczypi[INVESTIGATOR_813662] M, Bethge J, Arteta D, Ayala E, Danese S, van Hogezand RA, Panés J, Peña SA, Lukas M, Jewell DP, Schreiber S, Vermeire S, Sans M. Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project. Gut. 2013;62(11):1556-65. doi: 10.1136/gutjnl-2011-300777. 
Danese S, Klopocka M, Scherl EJ, Romatowski J, Allegretti JR, Peeva E, Vincent MS, 
Schoenbeck U, Xi L, Ye Z, Hassan -Zahraee M, Rath N, Li G, Neelakantan S, Banfield C, Lepsy 
C, Chandra D, Hung KE. DOP72 Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of ulcerative colitis: The open- label, multicentre, Phase 2a TUSCANY 
study [abstract]. Journal of Crohn's and Colitis. 2020;14(Supplement_1):S108-S10. doi: 10.1093/ecco-jcc/jjz203.111. 
Daperno M, D'Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, 
Pera A, Gevers A, Mary JY, Colombel JF, Rutgeerts P. Development and validation of a new, 
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 90 of 94 simplified endoscopic activity score for Crohn's disease: the SES -CD. Gastrointest Endosc. 
2004;60(4):505-12. doi: 10.1016/s0016-5107(04)[ZIP_CODE]-4. 
Feagan BG, Sandborn WJ, D'Haens G, Panés J, Kaser A, Ferrante M, Louis E, Franchimont D, 
Dewit  O, Seidler U, Kim KJ, Neurath MF, Schreiber S, Scholl P, Pamulapati C, Lalovic B, 
Visvanathan S, Padula SJ, Herichova I, Soaita A, Hall DB, Böcher WO. Induction therapy with the selective interleukin -23 inhibitor risankizumab in patients with moderate- to-severe Crohn's 
disease: a randomised, double- blind, placebo -controlled phase 2 study. Lancet. 
2017;389([ZIP_CODE]):1699-709. doi: 10.1016/s0140-6736(17)[ZIP_CODE]-6. 
Ferdinand JR, Richard AC, Meylan F, Al-Shamkhani A, Siegel RM. Cleavage of TL1A 
Differentially Regul ates Its Effects on Innate and Adaptive Immune Cells. J Immunol. 
2018;200(4):1360-9. doi: 10.4049/jimmunol.1700891. 
Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, Tompkins C. A new 
measure of health status for clinical trials in inflamm atory bowel disease. Gastroenterology. 
1989;96(3):804-10. 
Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease 
activity index. McMaster IBD Study Group. J Clin Gastroenterol. 1995;20(1):27-32. 
Moskovitz DN, Daperno M, Assche GA. Defining and validating cut- offs for the Simple 
Endocopic Score for Crohn's Disease. Gastroenterology. 2007;132:S1097. NCI. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Bethesda (MD): 
National Cancer Institute; 2017. Available from: ttps://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50. 
Prehn JL, Thomas LS, Landers CJ, Yu QT, Michelsen KS, Targan SR. The T cell costimulator 
TL1A is induced by [CONTACT_818635]. J Immunol. 2007;178(7):4033-8. doi: 10.4049/jimmunol.178.7.4033. 
Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, 
Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in pa tients with Crohn's disease. N Engl J Med. 1999;340(18):1398-405. 
doi: 10.1056/nejm199905063401804. 
Richard AC, Ferdinand JR, Meylan F, Hayes ET, Gabay O, Siegel RM. The TNF- family 
cytokine TL1A: from lymphocyte costimulator to disease co- conspi[INVESTIGATOR_13521]. J Leukoc Biol. 
2015;98(3):333-45. doi: 10.1189/jlb.3RI0315-095R. 
Roberts‑Thomson IC, Fon J, Uylaki W, Cummins AG, Barry S. Cells, cytokines and 
inflammatory bowel disease: a clinical perspective. Expert Rev Gastroenterol Hepatol. 2011;5(6):703-16. doi: 10.1586/egh.11.74. 
Roda G, Jharap B, Neeraj N, Colombel J-F. Loss of Response to Anti- TNFs: Definition, 
Epi[INVESTIGATOR_623], and Management. Clinical and translational gastroenterology. 2016;7(1):e135. 
doi: 10.1038/ctg.2015.63. 
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 91 of 94 Sands B, Sandborn W, Peyrin-Biroulet L, Higgins P, Hirai F, Belin R, Valderas E, Miller D, Morgan- Cox M, Naegeli A, Pollack P, Tuttle J, Imaeda H. Efficacy and Safety of Mirikizumab 
(LY3074828) in a Phase 2 Study of Patients with Crohn's Disease. Gastroenterology. 2019;156:S-216. doi: 10.1016/S0016-5085(19)[ZIP_CODE]-4. 
Selinger C, Sandborn W, Panes J, Jones J, Hassanali A, Jacob R, Sharafali Z, Oh Y, Tole S. 
Etrolizumab as induction therapy in moderate to severe Crohn's disease: results from BERGAMOT cohort 1. Gut. 2018;67(Suppl 1):A1–A304. doi: 10.1136/gutjnl-2018-BSGAbstracts.106. 
Shih DQ, Zheng L, Zhang X, Zhang H, Kanazawa Y, Ichikawa R, Wallace KL, Chen J, 
Pothoulakis C, Koon HW, Targan SR. Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis. Mucosal immunology. 2014;7(6):1492-503. doi: 10.1038/mi.2014.37. 
Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel 
diseases. Gastroenterology. 2011;140(6):1756-67. doi: 10.1053/j.gastro.2011.02.016. 
Valatas V, Kolios G, Bamias G. TL1A (TNFSF 15) and DR3 (TNFRSF25): A Co- stimulatory 
System of Cytokines With Diverse Functions in Gut Mucosal Immunity. Frontiers in 
immunology. 2019;10:583-. doi: 10.3389/fimmu.2019.[ZIP_CODE]. 
Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, Klopocka M, Goldis 
A, Wisniewska -Jarosinska M, Baranovsky A, Sike R, Stoyanova K, Tasset C, Van der Aa A, 
Harrison P. Clinical remission in patients with moderate -to-severe Crohn's disease treated with 
filgotinib (the FITZROY study): results from a phase 2, do uble-blind, randomised, placebo-
controlled trial. Lancet. 2017;389([ZIP_CODE]):266-75. doi: 10.1016/s0140-6736(16)[ZIP_CODE]-5. 
Yamazaki K, McGovern D, Ragoussis J, Paolucci M, Butler H, Jewell D, Cardon L, Takazoe M, 
Tanaka T, Ichimori T, Saito S, Sekine A, Iida A, Takahashi A, Tsunoda T, Lathrop M, Nakamura Y. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's 
disease. Hum Mol Genet. 2005;14(22):3499-506. doi: 10.1093/hmg/ddi379. 
Yang SK, Lim J, Chang HS, Lee I, Li Y, Liu J, Song K. Association of TNFSF15 with Crohn's 
disease in Koreans. Am J Gastroenterol. 2008;103(6):1437-42. doi: 10.1111/j.1572‑0241.2007.[ZIP_CODE].x.  
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 92 of 94 16 APPENDIX 
16.1 Simple Endoscopic Score for Crohn’s Disease (SES- CD) 
The Simple Endoscopic Score for Crohn’s  Disease (SES -CD) assesses the size of mucosal 
ulcers, the ulcerated surface, the endoscopic extension , and the presence of stenosis.  
Ulcers - scored according to size  
0 = no ulcers  
1 = aphthous (0.1 - 0.5 cm)  
2 = large (0.5 - 2 cm)  
3 = very large (> 2 cm)  
 
Proportion of the surface covered by [CONTACT_818623]  
0 = none  
1 = < 10%  
2 = 10 - 30% 
3 = > 30%  
 
Proportion of affected surface with any other lesions according to extent  
0 = unaffected segment  
1 = < 50%  
2 = 50 - 75% 
3 = > 75% 
 
Stenosis (single or multiple, and whether the colonoscopy could pass through the narrow 
lumen)  
0 = none  
1 = single, can be passed  
2 = multiple, can be passed  
3 = cannot be passed  
  
PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 93 of 94 16.2 Crohn’s Disease Activity Index (CDAI)  
The Crohn’s disease activity index ( CDAI ) scores range from 1 to approximately 600, with 
higher scores indicating more severe disease. Eight variables comprise the components of the 
CDAI score  (modified from Best  1976). Modification limits the c ontribution of the weight 
variable to no more than 10 points in negative contribution.  
 
  

PRA023 
Protocol PR200 -103 Version 4.0 (28 June 2022) 
Prometheus Biosciences, Inc.  Confidential  Page 94 of 94 16.3 Perianal Disease Activity Index (PDAI)  
The perianal disease activity index (PDAI) score includes the evaluation of 5 elements:  
1. discharge  
2. pain 
3. restriction of sexual activity  
4. type of perianal disease 
5. degree of induration 
Each category is graded on a 5- point Likert  scale ranging from no symptoms (score of 0) to severe 
symptoms (score of 4), with a range of 0 to 20; a higher score indicates more severe disease.  
 
